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1. ABSTRACT
The glomerular epithelial cells and their intercellular junctions, termed 
slit diaphragms, are essential components of the fi ltration barrier in the 
kidney glomerulus. Nephrin is a transmembrane adhesion protein of the 
slit diaphragm and a signalling molecule regulating podocyte physiol-
ogy. In congenital nephrotic syndrome of the Finnish type, mutation of 
nephrin leads to disruption of the permeability barrier and leakage of 
plasma proteins into the urine. This doctoral thesis hypothesises that 
novel nephrin-associated molecules are involved in the function of the 
fi ltration barrier in health and disease.
Bioinformatics tools were utilized to identify nephrin-like molecules 
in genomic databases, and their distribution in the kidney and other tis-
sues was investigated. Filtrin, a novel nephrin homologue, is expressed 
in the glomerular podocytes and, according to immunoelectron micros-
copy, localizes at the slit diaphragm. Interestingly, the nephrin and fi ltrin 
genes, NPHS1 and KIRREL2, locate in a head-to-head orientation on chro-
mosome 19q13.12. Another nephrin-like molecule, Nphs1as was cloned 
in the mouse, however, no expression was detected in the kidney but 
instead in the brain and lymphoid tissue. Notably, Nphs1as is transcribed 
from the nephrin locus in an antisense orientation. The glomerular mRNA 
and protein levels of fi ltrin were measured in kidney biopsies of patients 
with proteinuric diseases, and marked reduction of fi ltrin mRNA levels 
was detected in the proteinuric samples as compared to controls. In ad-
dition, altered distribution of fi ltrin in injured glomeruli was observed, 
with the most prominent decrease of the expression in focal segmental 
glomerulosclerosis. The role of the slit diaphragm-associated genes for 
the development of diabetic nephropathy was investigated by analys-
ing single nucleotide polymorphisms. The genes encoding fi ltrin, densin-
180, NEPH1, podocin, and α-actinin-4 were analysed, and polymorphisms 
at the α-actinin-4 gene were associated with diabetic nephropathy in a 
gender-dependent manner. 
Filtrin is a novel podocyte-expressed protein with localization at the slit 
diaphragm, and the downregulation of fi ltrin seems to be characteristic for 
human proteinuric diseases. In the context of the crucial role of nephrin 
for the glomerular fi lter, fi ltrin appears to be a potential candidate mol-
ecule for proteinuria. Although not expressed in the kidney, the nephrin 
antisense Nphs1as may regulate the expression of nephrin in extrarenal 
tissues. The genetic association analysis suggested that the α-actinin-4 
gene, encoding an actin-fi lament cross-linking protein of the podocytes, 
may contribute to susceptibility for diabetic nephropathy. 
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2. REVIEW OF THE LITERATURE
2.1. Glomerular capillary wall as the fi ltration barrier in 
the kidney glomerulus
The kidney is a vital organ responsible for secreting metabolic end-prod-
ucts into the urine. In addition, the kidney maintains body homeostasis 
by regulating the fl uid, acid-base and electrolyte balance. The nephron 
is the basic functional unit in the kidney, and primary urine is produced 
in the fi rst part of the nephron, the glomerulus, which is a capillary tuft 
surrounded by a urinary space and the Bowman’s capsule [1].
The mechanism of glomerular fi ltration has remained an enigma of 
nephrology for decades. Notably, about 180 liters of primary urine is fi l-
tered through the glomerular capillary wall every day, which is essential 
for the effi cient excretion of metabolic end-products from the circula-
tion. At the same time, this fi lter can retain albumin and other crucial 
plasma proteins in the circulation, but the fi lter itself does not clog in 
spite of the enormous load of 15 kg of protein that the kidneys handle 
every day [1]. The prevailing view is that the composite effect of all layers 
of the glomerular capillary wall contributes to the charge- and size selec-
tive properties of the fi ltration barrier (Figure 1). 
Blood enters the capillary tuft through the afferent arteriole, which 
branches into smaller capillaries [1]. The high capillary pressure (55 mmHg) 
forces water and small molecules through the capillary wall. It has been es-
timated that approximately 20% of the plasma volume is fi ltered through 
the capillary wall, the rest exits the glomerulus via the efferent arteriole 
[1]. The capillary endothelial cells are thin cells lining the luminal side of the 
glomerular basement membrane (GBM) (Figure 1) and they represent the 
initial barrier to the blood constituents. These cells have a porous structure 
with round to oval fenestrae of 70-100 nm in diameter [1]. The fenestrae 
and the whole luminal side of the cell are covered by a special glycocalyx 
with a negative charge due to sialic acid containing glycoproteins and lip-
ids [2, 3]. The negative charge of the endothelial cells may account for the 
charge selectivity of the permeability barrier [4].
The mesangial cells support the glomerular structure on the endocap-
illary side [5]. Similar to the smooth muscle cells, the mesangial cells con-
tract in response to vasoactive agents and have thus been proposed to 
regulate glomerular fi ltration. These cells also have phagocytotic proper-
ties and secrete bioactive substances such as prostaglandins [6, 7].
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The GBM separates the endothelial cells from the podocytes (Figure 1). 
This membrane is a meshwork of glycoproteins (type IV collagen [α3α4α5], 
laminin-11 [α5β2γ1], and nidogen/entactin) and proteoglycans (agrin and 
perlecan) with a high water content (reviewed in [8, 9]). The GBM car-
ries an anionic charge due to negatively charged glycosaminoglycan side 
chains of perlecan and agrin.
Podocytes (Greek ‘pod’, foot) cover the GBM from the urinary side 
with cellular projections known as foot processes (Figure 1; reviewed in 
[10]). The podocytes are terminally differentiated epithelial cells with an 
arborized structure similar to neurons. These cells are highly polarized 
with their apical side and the cell body facing the urinary side of the 
Bowman’s space, and foot processes are anchored to the GBM on the 
basal side in an integrin- and dystroglycan-dependent fashion [11-13]. 
Bundles of actin fi laments on the apical pole and the cortical actin net-
work support the structure of the foot processes [14].
The interdigitating foot processes are separated by a slit of 30-40 nm 
and bridged by a unique cell junction termed the ‘slit diaphragm’ [15]. 
In the pioneering work by Rodewald and Karnovsky, the slit diaphragm 
was described as a zipper-like structure with a pore size corresponding 
to the dimensions of albumin [15]. Recent electron-tomographic data ac-
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Figure 1. Schematic structure of the glomerulus. Primary urine is produced in the 
glomerulus, which is a capillary tuft surrounded by a urinary space and the Bowman’s 
capsule. Modifi ed from [107].
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cords with this view, revealing winding strands that form connections at 
the midline of the slit [16]. Conceptually, the slit diaphragm represents 
the border between the basal and apical domains of the podocyte [17, 
18] and has been proposed to share properties of adherens and tight 
junctions [17, 19].
In the 1960s, tracer studies were launched to decipher the molecular 
barrier of the glomerular capillary wall. Experiments using ferritin and 
dextrans of different molecular weights as molecular markers indicated 
that the molecules of the size of albumin or larger cannot penetrate the 
GBM (reviewed in [20]). However, this approach neglected the infl uence 
of charge of the molecular components of the barrier on fi ltration. More 
conclusive results were obtained by using ferritins with anionic, neutral 
and cationic charge, and these experiments suggested that the GBM and 
endothelial cells prevent the passage of anionic molecules, whereas the 
fi ltration slit diaphragm appeared to retard the passage of molecules 
with positive charge [21]. However, this issue has remained a matter of 
debate. A gel permeation/diffusion hypothesis suggests that GBM is the 
size-selective barrier and the slit diaphragm only provides resistance to 
water fl ow [22], but completely contrasting views have also been pro-
posed [23, 24]. 
A set of discoveries have brought the slit diaphragm into focus. In 
1988, it was demonstrated that an injection of the monoclonal antibody 
5-1-6, directed against the slit diaphragm, induced proteinuria in rats 
[25]. Later, it was ascertained that the antibody reacted with the slit di-
aphragm protein nephrin [26]. The discovery of the causative nephrin 
gene (NPHS1) for congenital nephrotic syndrome of the Finnish type in 
1998 [27], and the elucidation of the genetic defects in other inherited 
nephropathies (reviewed in chapter 2.5) have launched a new era in ne-
phrology.
2.2. The slit diaphragm is an adhesion and signalling 
complex in the podocytes
The slit diaphragm has been described as a ‘modifi ed adherens junction’ 
by Reiser and co-workers [19]. This cell-cell contact shares characteristics 
of the adherens junction (expression of P-cadherin [19]) and tight junc-
tion (zonula occludens-1 [17]), and the expression of slit diaphragm-spe-
cifi c proteins refl ects its unique properties (e.g. podocin [28]). The mo-
lecular composition of the slit diaphragm is reviewed in this chapter with 
special reference to the functions attributed to these proteins. Figure 2 
summarizes the principal components of the slit diaphragm and the as-
sociated cytoplasmic adhesion complex.
The slit diaphragm can be considered an epithelial cell adhesion junc-
tion and a fence between the apical and basal domains of the podocyte 
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foot processes [17, 18]. Tight junctions have usually been acknowledged 
for their function as a selective fi lter, but as illustrated by the permeabil-
ity assays (reviewed in chapter 2.1) and the multitude of slit diaphragm 
encoding genes behind hereditary proteinuria (chapter 2.5), the slit dia-
phragm also seems to serve a fi ltering function. Recently, the functions 
ascribed to the slit diaphragm have extended from a mere structural 
component to the regulator of transcriptional activity, apoptosis, and 
podocyte cytoskeleton (reviewed in [29-31]).
Nephrin
Nephrin (the offi cial gene name by HUGO nomenclature NPHS1) is an 
integral adhesion molecule and a structural component of the slit dia-
phragm [32-34]. This protein belongs to the immunoglobulin superfamily 
with eight extracellular immunoglobulin-like domains followed by a 
fi bronectin type III domain, a single-span transmembrane region, and a 
C-terminal intracellular domain. A hypothetical model of the homophilic 
interaction of nephrin molecules was introduced already in the fi rst re-
ports of nephrin [34], suggesting that nephrin molecules from adjacent 
foot processes would interact via their extracellular immunoglobulin-like 
domains and thus contribute to the fi lamentous diaphragm observed be-
tween foot processes. Subsequent experimental studies have provided 
support for this view [35-37].
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Figure 2. The slit diaphragm is a unique cell-cell junction between the podocyte foot 
processes. Proteins of the immunoglobulin and cadherin superfamilies comprise the 
extracellular adhesion complex, while several adaptor and scaffolding proteins are 
located on the intracellular side. GBM, glomerular basement membrane. Modifi ed 
from [61].
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Nephrin resides in lipid rafts on the plasma membrane, and tyrosine 
residues of nephrin are phosphorylated upon foot process effacement 
[38, 39]. Furthermore, nephrin associates with and is phosphorylated by 
Src family kinase Fyn which stimulates intracellular signalling [40, 41]. 
Emphasizing the role of nephrin as a signaling protein, the intracellular 
tyrosine phosphorylated residues serve as potential docking sites for p85, 
the regulatory subunit of phosphoinositide 3-OH kinase [42], and for the 
adaptor protein Nck [39, 43], and these interactions appear to regulate 
the actin cytoskeleton and apoptosis in podocytes [39, 42, 43]. In addi-
tion, phosphorylation of nephrin seems to regulate gene expression in 
the podocytes, and this is facilitated by the interaction with another slit 
diaphragm protein, podocin [41, 44]. Similar to other plasma membrane 
receptors, nephrin is endocytosed by β-arrestin in a phosphorylation de-
pendent manner [45].
Regulation of nephrin in acquired proteinuric diseases has been under 
intensive study, and altered protein and mRNA levels are found both in 
experimental animal models and human diseases (e.g. [46-48]). In par-
ticular, downregulation of nephrin in diabetic nephropathy is well es-
tablished and, at least partially, mediated by angiotensin II and glycated 
albumin [49-51]. However, repression of nephrin expression might also 
be partially explained by the reduced number of podocytes per glomeru-
lus [52].
Nephrin-like proteins NEPH1, NEPH2 and fi ltrin
The cloning of NEPH1 (KIRREL) in 2001 led to the establishment of a pro-
tein family including two other closely related proteins, NEPH2 (KIRREL3) 
and fi ltrin (KIRREL2) [53-56]. Filtrin is also known as NEPH3. These pro-
teins share a common domain architecture with fi ve extracellular immu-
noglobulin-like domains and a short intracellular domain of around 200 
amino acids [57]. Within podocytes, NEPH1 and NEPH2 localize at the 
podocyte slit diaphragm [37, 54, 58] (Figure 2). In NEPH1-defi cient mice, 
the podocyte foot processes are effaced along the GBM, and the mice 
exhibit severe proteinuria [53]. Similarly to nephrin-defi cient mice, the 
pups die during the early postnatal period [53].
Soon after the cloning of nephrin-like proteins, the hypothesis of their 
potential interaction with nephrin was presented. Indeed, the extracel-
lular domains of NEPH1 and NEPH2 appear to interact with nephrin, and 
the interactions are mediated by several extracellular immunoglobulin-
like domains [35, 37, 54, 58]. NEPH2 has also been reported to form ho-
modimers [54], whereas the data concerning the possible homodimerisa-
tion of NEPH1 remains controversial [35, 37, 58]. Similarly to nephrin, 
NEPH1 resides in lipid rafts [37, 54]. The extracellular domain of NEPH2 is 
shedded from the plasma membrane by matrix metalloproteinases [54, 
59], and seems to leak into the urine of both healthy individuals and 
proteinuric patients.
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The physiological importance of NEPH1-nephrin interaction has been 
clarifi ed in vivo by injecting a combination of anti-NEPH1 and anti-
 nephrin antibodies into rats. The antibody mixture induced a transient 
pro teinuria in mice, whereas injection of anti-NEPH1 or anti-nephrin an-
tibodies alone did not cause any changes. Even though the podocyte 
foot processes and slit diaphragms remained intact during this experi-
ment, the expression of ZO-1, an intracellular binding partner of NEPH1, 
was considerably reduced [58].
In their intracellular part, NEPH1, NEPH2 and fi ltrin share a motif of 
nine conserved amino acids surrounding an SH2-binding site of growth 
factor receptor-bound protein 2 (Grb2) [57]. Sellin and colleagues hypoth-
esized that this domain of nine amino acids could mediate interaction 
between the NEPH1 and podocin. They ascertained that both a single 
point mutation in the Grb2-binding site and tyrosine phosphorylation of 
this motif by Src kinases inhibited the interaction between the C-terminal 
domain of NEPH1 and podocin [57]. NEPH1 interaction via its intracellu-
lar domain with podocin was also verifi ed by immunoprecipitation [57]. 
Furthermore, co-expression of NEPH1 and the IL2-inducible T-cell kinase 
resulted in a marked activation of the transcription factor AP-1, arguing 
for a role of NEPH1 as a signalling molecule [57].
Since the C-terminal end of nephrin-like proteins contains a putative 
PDZ-binding motif, the interaction between them and a PDZ-domain-
bearing protein ZO-1 has been assessed [60]. The interaction occurs both 
in vitro and in vivo and has been mapped to the fi rst PDZ domain of ZO-1 
and the last three amino acids of the intracellular domain of NEPH1. This 
conclusion accords with the data presented by Liu and colleagues [58]. 
The interaction substantially increased signal transduction as measured 
by AP-1 activity and induced tyrosine phosphorylation of NEPH1 [60].
Cadherin superfamily proteins
To date, only a few proteins in addition to nephrin and nephrin-like pro-
teins have been localized to the extracellular adhesion junction of the 
slit diaphragm (Figure 2). These proteins include P-cadherin (CDH3) [19] 
and a recently reported VE-cadherin (CDH5) [61], originally attributed 
to its function in the vascular endothelium [62]. In a podocyte cell line, 
P-cadherin also recruites several catenins to the intracellular side [19]. 
Even though reduced levels of P-cadherin have been reported in dia-
betic nephropathy [63], the signifi cance of P-cadherin for maintaining 
the glomerular fi lter remains elusive, since the respective P-cadherin-de-
fi cient mice show no kidney dysfunction [64]. 
In addition to classical cadherins, a large protocadherin FAT1 (FAT) with 
34 extracellular cadherin repeats seems to be an essential component of 
the slit diaphragm, as refl ected by the lethal phenotype of Fat1-defi cient 
mice [65, 66]. These mice suffer from perinatal lethality and their foot 
processes are fused according to an electron microscopic examination 
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[66]. FAT1 is acknowledged for its function as a regulator of actin polym-
erization (via its interaction with Ena/VASP proteins) and, in addition, in 
the establishment of cell polarity [67].
Intracellular scaffolding and signalling proteins
A number of peripheral membrane proteins locate on the intracellular 
side of the slit diaphragm, where they link the immunoglobulin super-
family members and cadherins to the cortical actin cytoskeleton [68, 69]. 
Before nephrin, ZO-1 (TJP1) was the only identifi ed slit diaphragm-asso-
ciated protein in the podocytes [17]. It is actually a typical tight junction 
protein, and the ZO-1 isoform without the motif-alpha is expressed in 
the slit diaphragms [70]. ZO-1 is localized on the intracellular side of the 
lateral foot process membranes, where it binds the nephrin-like proteins 
via its PDZ-domain [60]. 
Nephrin also provides a nexus for several binding partners on the 
intracellular side (Figure 2). Proteins including CD2-associated protein 
(CD2AP) [71, 72] and podocin [73] are located on the lateral foot process 
membrane and they are crucial for the proper fi ltration function. Podocin 
(NPHS2) is a member of the prohibitin-domain proteins and expressed al-
most exclusively in the podocytes [28, 73]. Podocin forms homo-oligomers 
and is a constituent of lipid rafts [28, 74], where it binds cholesterol via its 
prohibitin-domain [75]. Podocin also functionally interacts with the slit 
diaphragm protein TRPC6 [76, 77], a non-selective cation channel, and 
regulates the activity of this channel in a cholesterol dependent fashion 
[75]. It has been speculated that podocin and TRPC6 could act as sensors 
for the intraglomerular pressure and/or glomerular fi ltration in the kid-
ney [75]. Podocin associates via its C-terminal domain with nephrin and 
CD2AP [28, 44] and escorts nephrin to the lipid rafts [74]. 
CD2AP is an adaptor protein, originally recognized for its function in 
the immunological synapse [78]. CD2AP is an actin-associated protein in 
the podocytes [79, 80], but immunoelectron microscopic data and the 
reported interaction with nephrin suggest localization also at the slit 
diaphragm [72, 81]. In the close vicinity of the slit diaphragm resides an 
actin-bundling protein, α-actinin-4 (ACTN4) [82, 83]. Transgenic animal 
models of Actn4 have pinpointed a role for this molecule in cell motility 
and actin cytoskeleton regulation [84, 85] and also in the adhesion of po-
docytes to the GBM [86]. Densin-180 (LRRC7) is a founding member of a 
protein family containing several leucine-rich repeats and PDZ domains, 
and it had been originally identifi ed from the postsynaptic densities in 
the brain [87]. Recently, it has been reported as a novel nephrin-asso-
ciated protein at the slit diaphragm [88] and as a potential interaction 
partner for α-actinin-4 [89]. 
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2.3. Development of the slit diaphragm from a tight 
junction
Development of the metanephric mammalian kidney is a process that in-
volves reciprocal interaction of two tissue components, the mesenchymal 
blastema and the ureteric bud, originally the mesoderm-derived Wolf-
fi an duct [90]. The glomerular development involves a series of events 
that initiates with the condensation of metanephric mesenchyme cells 
next to the tip of the ureteric bud [90]. These cells undergo mesenchyme-
to-epithelium transition and form an epithelial vesicle, which gives rise 
to all the segments of the nephron, including the glomerulus and the 
proximal and distal tubules [90]. Glomerular anlagen are fi rst visible at 
the S-shape body stage, which has developed from the vesicle [91] (Figure 
3). At this stage, the precursor cells of the endothelium and mesangium 
invade the proximal part of the S-shaped body, and the entity eventually 
forms a vascularized glomerulus [91, 92].
Visceral epithelial cells lining the presumptive Bowman’s space rep-
resent the future podocytes (Figure 3). At the early S-shape body stage, 
the cells are joined by ZO-1-positive apical tight junctions [17] and are 
fi rmly attached to the nascent basement membrane, a fence between 
the epithelial and capillary compartments [91]. During podocyte differ-
entiation, the junctional complexes between the cell membranes migrate 
down towards the basal side. Eventually, a continuous intercellular space 
becomes visible between the cells, and ladder-like junctions are occasion-
ally seen between the cells [91]. The layer of the future podocytes forms 
a cup around the developing capillary loops, and the formation and in-
terdigitation of the foot processes begins (Figure 3). At the capillary loop 
stage, nephrin and ZO-1 localize at the cell-cell contacts between the 
developing podocytes [17, 93]. The foot processes surround the capillar-
ies, and the tight junctions are gradually replaced with the mature slit 
diaphragms (Figure 3). [91]
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Figure 3. Development of the slit diaphragm. During the development the apical 
junctional complexes migrate towards the basal slit and fi nally mature into slit 
diaphragms. Drawn after [235].
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In experimental nephrosis and human proteinuric diseases, foot proc-
ess effacement is often observed [94, 95]. It has been postulated that the 
loss of the foot process architecture and appearance of tight junctions or 
ladder-like structures replacing the slit diaphragms corresponds to a re-
verse of the podocyte into more primitive developmental stages [91]. For 
example, in the puromycin aminonucleoside nephrosis of rats, tight junc-
tions or ladder-like structures reappear in the intercellular space [94], and 
this condition may be reversible with the restoration of the foot process 
architecture. The elucidation of the morphological basis of proteinuria 
has lead to the view that podocytes are involved in the progression of 
proteinuric diseases (reviewed in [96]).
2.4. Proteinuria is a hallmark of glomerular injury
Minimal change disease (MCD), focal segmental glomerulosclerosis 
(FSGS), and membranous glomerulopathy (MGN) are primary glomerular 
diseases manifesting as nephrotic syndrome [97]. These diseases are clini-
cally characterized by heavy proteinuria (i.e. leakage of high molecular 
weight proteins into the blood fi ltrate and urine), hypoalbuminemia, 
hyperlipidemia, and oedema [97]. Diabetic nephropathy and hyperten-
sive nephropathy are secondary disorders that affect the glomerulus and 
present a more insidious pathogenetic process. The clinical sequelae of 
proteinuric diseases are well-described, but the pathogenetic mecha-
nisms at the molecular level have remained elusive. The main question 
is, why the glomerulus becomes leaky under pathological conditions. It 
has become evident that a common denominator for these diseases is 
podocyte injury (reviewed in [98]).
Minimal change disease
Minimal change disease is characterized by the nephrotic syndrome 
without glomerular lesions observed in light microscopy (fi rst described 
by Munk in 1916 [99]). However, in electron microscopic examination, 
effacement of the podocyte foot processes is frequently encountered, 
while the structure of GBM seems unaltered [95]. This suggests that po-
docyte injury is involved in the pathogenesis of MCD [95]. MCD is the 
most common primary nephrotic syndrome in children, and it accounts 
for about 20% of primary glomerular disease in adults [100]. 
MCD can often be classifi ed as ‘primary’, but secondary forms also 
exist in association with tumours, toxic or allergic reactions, infections, 
and autoimmune diseases [97]. Immune-complex deposition or comple-
ment activation in the glomerulus of the patients with MCD has not been 
reported. Instead, it has been postulated that MCD is a disorder of T cell 
function, where abnormal secretion of cytokines affecting the glomeru-
lar capillary permeability may be involved [101, 102]. MCD responds ef-
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fectively to treatment with corticosteroids (prednisone) in children; in 
adults, steroid resistance and relapses are, on the other hand, common 
[103]. Gradual transition from MCD into focal segmental glomeruloscle-
rosis has been reported making these diseases both diagnostically and 
therapeutically challenging [104]. The expression ratio of podocin to 
synaptopodin, two podocyte-expressed genes, has recently been sug-
gested for disease stratifi cation [47].
Focal segmental glomerulosclerosis
The name ‘focal segmental glomerulosclerosis’ describes the lesions 
observed in the kidney in this disease: Scarring involves only some of 
the glomeruli (focal), and in the affected glomeruli, only a part of the 
glomerulus appears sclerotic (segmental) (fi rst description published in 
[105]). Several variants of FSGS (e.g. collapsing, glomerular tip, or cellular 
variant) can be separated in histological examination [97]. Podocyte in-
jury and dedifferentiation seems to be a primary cause of the disease [98, 
106], and formation of scars may be a sign of a reparative process after 
podocyte injury [107]. FSGS is the cause of primary glomerular disease in 
about 15% of adults patients, but is less common in children [100].
FSGS can be considered either primary or secondary if associated with 
HIV, toxic compounds or drugs [97]. In some patients with primary FSGS, 
it has been speculated that a circulating factor underlies the glomerular 
permeability changes [108]. Interestingly, several familial forms of FSGS 
have been discovered with mutations in the podocyte-expressed genes 
(reviewed in chapter 2.5). FSGS responds poorly to corticosteroid treat-
ment, and often progresses to chronic renal failure [103]. Anti-prolifera-
tive agents (e.g. cyclophosphamide) may be effective for the treatment 
of the steroid-resistant cases [103]. Notably, the prognosis of patients car-
rying mutations in genes linked to FSGS is poor.
Membranous glomerulopathy
Membranous glomerulopathy is characterized by formation of subepi-
thelial immune deposits of IgG and a diffusively thickened GBM [97]. Po-
docyte foot process effacement is observed at the ultrastructural level 
[97, 109]. Even though MGN progresses slowly, it is a common cause of 
primary glomerular disease accounting for about 40% of cases in adults, 
but it is less common in children [100].
The formation of immune complexes against the podocyte-membrane 
proteins, with yet unidentifi ed antigens, seems to trigger the membrane 
thickening (reviewed in [109]). In rare cases of neonatal membranous ne-
phropathy, neutral endopeptidase in the podocyte membrane has been 
identifi ed as a target for circulating antibodies [110]. In Heymann nephri-
tis, a rat model of MGN, the antigen is the podocyte membrane protein 
megalin, which is a member of the LDL-receptor subfamily [111, 112]. 
Mechanistically, the immune complexes lead to complement activation 
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and generation of C5b-9 membrane-attack complexes on the podocyte 
membranes, and formation of oxygen radicals by the injured podocytes 
seems to promote the glomerular damage [110, 113, 114]. Corticoster-
oids alone have been reported to be ineffective in the therapy [103]; The 
combination of anti-proliferative agents with corticosteroids is consid-
ered a better approach [103].
Hypertensive nephropathy
Hypertensive nephropathy is histologically characterized by the accumu-
lation of hyaline in the walls of arteries and arterioles, collapse of the 
glomerular tuft, and glomerulosclerosis [115]. It has been estimated that 
hypertensive male patients suffer from manifold higher relative risk of 
developing renal failure than subjects with optimal blood pressure [116]. 
Malignant hypertension is recognized as a distinct cause of renal failure, 
while the link between essential hypertension and nephropathy is less 
well determined [117]. 
The podocytes are sensitive to injury, and animal models of hyper-
tension suggest that podocyte failure in hypertension may promote the 
formation of glomerulosclerosis [118, 119]. It has been postulated that 
mechanical strain due to increased intraglomerular pressure is the un-
derlying cause for podocyte injury [98, 120, 121]. Glomerular ischemia 
and/or hyperfi ltration have also been suggested to promote glomerular 
injury. Notably, systemic hypertension and/or elevated intraglomerular 
pressure associate with other types of nephropathy, e.g. diabetic neph-
ropathy [115]. Control of hypertension with antihypertensive agents is 
essential for the treatment of the disease.
Diabetic nephropathy
Diabetic nephropathy is the most common cause of nephrotic proteinu-
ria [122]. It has been estimated that approximately one-third of patients 
with diabetes develop diabetic nephropathy [123, 124], which can be 
considered the most severe complication of diabetes due to the associ-
ated several fold increased risk of cardiovascular disease and mortality 
[125, 126]. During the course of diabetes, the incidence of diabetic ne-
phropathy is not linear, but it increases until 15 years after the onset of 
diabetes and declines thereafter [123].
Microalbuminuria is the fi rst sign of glomerular dysfunction in type 
1 diabetes and is considered a powerful predictor of progression to 
overt nephropathy [127]. Microalbuminuria refl ects the alterations in 
the glomerular capillary wall at the early stage of the disease: Increase 
in podocyte foot process width and reduced number of podocytes per 
glomerulus have been reported [128-130]. At later stages of the disease, 
nodular glomerulosclerosis with expansion of the mesangial matrix and 
thickened GBM can be observed [131]. It should be noted that diabetic 
nephropathy is part of a generalized microvascular damage occurring af-
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ter prolonged hyperglycaemia [132]. During this process, involvement of 
the renin-angiotensin system, advanced glycosylation end-products and 
reactive oxygen species have been indicated as pathogenetic mechanisms 
(reviewed in [133]). Importantly, angiotensin II seems to have direct ef-
fects on the podocytes, causing e.g. podocyte apoptosis and cytoskeleton 
rearrangement [120, 134].
Hyperglycaemia is the most important risk factor for diabetic neph-
ropathy both in type 1 and 2 diabetes [135, 136]. However, patients with 
poor glycaemic control do not necessarily develop nephropathy, indicat-
ing that other factors are involved. Additional risk factors include smok-
ing [137], hyperlipidemia [138], and insulin resistance even in patients 
with type 1 diabetes [139]. The prevailing view is that the combination 
of environmental and genetic risk factors (reviewed in chapter 2.5) is the 
driving force for the development of diabetic nephropathy.
Elimination of classical risk factors, improvement of glycaemic control, 
aggressive treatment of hypertension, and cessation of smoking are es-
sential for the prevention of the development of diabetic nephropathy. 
Currently used therapies for diabetic nephropathy focus on blocking the 
renin-angiotensin system with angiotensin-converting enzyme inhibitors 
and angiotensin receptor antagonists [140, 141].
2.5. Genetic basis of proteinuria
Milestone discoveries of the genetic basis of proteinuria have shed light 
on the molecular structure of glomerular capillary wall and have dis-
closed mutations in genes encoding adhesion proteins, components of 
cell cytoskeleton, and mediators of signal transduction (reviewed in [142-
144]). Notably, most of these proteins were located in the glomerular 
podocytes. Therefore, renal research has in recent years adopted a new 
concept of a ‘podocentric view of nephrology’ [145].
According to the classifi cation by Wilhelm Kriz [142], hereditary dis-
eases affecting the podocytes can be divided into two groups based on 
their age of onset. First, genetic defects manifesting at birth or soon af-
ter birth (‘early onset’) are characterized by the lack of or deformed slit 
diaphragms and/or nephrotic range proteinuria [142] (Table 1). Second, 
proteinuric disorders occurring from childhood to late adulthood can be 
regarded as a consequence of the reduced ability of the podocyte to re-
spond to physiological challenge, accounting for the later age of onset 
[142]. Typically, these diseases segregate in an autosomal-dominant pat-
tern in families with variable penetrance (Table 1).
The gene encoding the slitdiaphragm protein nephrin, NPHS1, is mu-
tated in congenital nephropathy of the Finnish type (CNF) [27]. This disor-
der was fi rst characterized by Hallman and co-workers in 1956 [146], and 
it belongs to the Finnish disease heritage [147], a term used to describe 
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Table 1. Hereditary proteinuric diseases classifi ed according to age at onset. Modifi ed from [142] 
and [143].
Disease Gene (protein)
Chromosomal 
region
Mode of 
inheritance References
Early onset
Congenital nephrotic syndrome of 
the Finnish type
NPHS1 (nephrin) 19q13.12 recessive [27]
Denys-Drash syndrome WT1 (WT1) 11p13 dominant [161]
Pierson’s syndrome LAMB2 (laminin β2 
chain)
3p21.31 recessive [152]
Nephrotic syndrome type 3 (NPHS3) PLCE1 (phospholipase 
C ε1
10q23.33 recessive [151]
Steroid-resistant nephrotic syndrome NPHS2 (podocin) 1q25.2 recessive [73]
Late onset
Alport syndrome COL4A3 (α3(IV)
collagen)
2q36.3 recessive / 
dominant
[228] [229] 
[230]
COL4A4 (α4(IV)
collagen)
2q36.3
COL4A5 (α5(IV)
collagen)
Xq22.3 X-linked [231]
Epstein and Fechtner syndromes MYH9 (non-muscle 
myosin heavy chain 9)
22q12.3 dominant [155]
Focal segmental glomerulosclerosis ACTN4 (α-actinin-4) 19q13.2 dominant [83]
Focal segmental glomerulosclerosis TRPC6 (TRPC6) 11q22.1 dominant [77] [76]
Frasier’s syndrome WT1 (WT1) 11p13 dominant [162]
Nail-patella syndrome LMX1B (LMX1B) 9q33.3 dominant [160]
The chromosomal regions are derived from the UCSC Genome Browser (March 2006 Assembly).
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diseases that occur more frequently in Finland than elsewhere in the Eu-
rope. In CNF, the podocyte foot processes are fl attened and effaced, and 
the slit diaphragms are missing [148, 149]. Affected babies suffer from 
massive treatment-resistant proteinuria already in utero [146, 150].
The NPHS2 gene encoding podocin is mutated in steroid-resistant ne-
phrotic syndrome [73]. Recently, a third nephrosis gene, namely phos-
pholipase C ε1 (PLCE1), was discovered, with expression in the developing 
and mature podocytes [151]. Interestingly, some patients with mutations 
in PLCE1 were steroid-sensitive, indicating that patients carrying certain 
mutations in PLCE1 could be cured. Laminin β2-chain is a component of 
mature glomerular basement membranes, and certain mutations in the 
human LAMB2 gene account for Pierson’s syndrome [152]. Pierson’s syn-
drome is characterized by congenital nephrosis with mesangial sclerosis 
and ocular defects [152].
Familial forms of focal segmental glomerulosclerosis (FSGS) with de-
fects in the non-selective cation channel TRPC6 [76, 77] and the actin-fi la-
ment cross-linking protein α-actinin-4 (ACTN4) [83] have been character-
ized. Interestingly, mutations of NPHS2 with later onset have also been 
reported in familial FSGS [153], and NPHS2 has been suggested to associ-
ate with microalbuminuria in the general population [154]. The impor-
tance of the podocyte cytoskeleton was further emphasized by the May-
Hegglin anomaly, and Sebastian, Epstein and Fechtner syndromes that 
involve mutations in the gene encoding the non-muscle myosin heavy 
chain 9 (MYH9) expressed in the podocytes [155]. In these syndromes, the 
patients suffer from macrothrombocytopenia and variably from other 
symptoms including proteinuria [156]. Alport syndrome involves muta-
tions in the genes encoding the constituents of type IV collagen (α3α4α5) 
of the GBM and presents with hematuria and progressive glomerular dis-
ease, hearing loss and ocular lesions (reviewed in [157]).
Transcription factors LMX1B and WT1 regulate several podocyte-ex-
pressed genes and are involved in the early phases of the kidney and 
podocyte differentiation [158, 159]. Mutations in the LMX1B gene have 
been mapped in patients with nail-patella syndrome, a dominantly in-
herited disorder with skeletal malformations and, in some patients, renal 
dysfunction due to glomerular lesions [160]. Variants in the Wilms tumor 
1 gene WT1 have variable phenotypes: The mutation spectrum of Denys-
Drash syndrome is broad covering the whole gene locus resulting in an 
early onset of nephropathy [161]. Patients with Denys-Drash syndrome 
suffer from generalized urogenital developmental abnormalities [161]. 
In Frasier syndrome, characterized by male pseudohermaphrodism and 
progressive glomerular disease, proteinuria develops later due to mu-
tations in the donor splice site of intron 9 of the WT1 gene [162]. Kriz 
classifi es nail-patella syndrome and Frasier syndrome in the late-onset 
group based on their clinical features, but emphasizes that the disease 
mechanisms are not well understood  [142].
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In diabetic nephropathy, familial clustering has been reported in 
several studies indicating the existence of a genetic component in the 
disease [163-166]. In the Finnish population, the sibling recurrent risk λs 
is 2.3, which indicates the risk that diabetic siblings of a nephropathic 
proband have compared to siblings of a proband without diabetic neph-
ropahty [163]. Furthermore, the albumin excretion rate and the extent of 
glomerular lesions seem to be partially heritable and genetically deter-
mined in families with patients with diabetes [167, 168]. 
Diabetic nephropathy can be considered a typical complex disease 
with multiple genetic loci that contribute to the disease development 
in combination with other biological effects (e.g. hyperglycaemia) [169]. 
Genome-wide screens using sib-pairs or case-control setting have re-
vealed potential susceptibility loci for diabetic nephropathy on chromo-
somes 10q and 3q [170-172]. Candidate gene studies have focused on 
the known biological pathways involved in the pathogenesis of diabetic 
nephropathy. These pathways include the genes of the renin-angiotensin 
system, and a recent meta-analysis of several studies support the involve-
ment of angiotensin I converting enzyme insertion/deletion polymor-
phism in the development of diabetic nephropathy [173]. However, most 
attempts to determine the effect of a genetic variant in a particular gene 
on the development of diabetic nephropathy have suffered from the lack 
of suffi cient statistical power (discussed in [174]).
Transgenic animal models have provided new insights in the genet-
ics of proteinuria. Defi ciency of the slit diaphragm proteins NEPH1, a 
nephrin-homologue, and FAT1, a member of the cadherin superfamily, 
was discovered to cause massive proteinuria and lethality in mouse [53, 
66]. Inactivation of the gene encoding CD2-associated protein (Cd2ap) in 
mice results in congenital nephrotic syndrome and death at 6 to 7 weeks 
of age [71]. Interestingly, haploinsuffi ciency of CD2AP may also be in-
volved in human glomerular disease  [175]. To my knowledge, no genetic 
defect has been mapped to the human homologues of NEPH1 and FAT1 
in proteinuria.
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3. AIMS OF THE STUDY
Since the discovery of the causative gene for the congenital nephrotic 
syndrome of the Finnish type, NPHS1, and the identifi cation of the gene 
product nephrin as a constituent of the slit diaphragm [27, 32, 34], the 
prevailing view has been that the slit diaphragms are of pivotal impor-
tance for the molecular sieve in the kidney glomerulus. This thesis hy-
pothesized that additional nephrin-associated molecules participate in 
maintaining the function of the fi ltration barrier in health and disease.
The specifi c aims of this thesis were to evaluate the following:
1. To determine the expression and localization of fi ltrin, a novel ne-
phrin-like protein, in the kidney.
2. To clone and characterize the nephrin antisense transcript Nphs1as in 
mouse.
3. To elucidate the expression pattern and distribution of fi ltrin in the 
kidneys of patients with proteinuric diseases.
4. To investigate the genetic association of the nephrin-associated genes 
densin-180 (LRRC7), NEPH1 (KIRREL), podocin (NPHS2), fi ltrin (KIR-
REL2), and α-actinin-4 (ACTN4) with diabetic nephropathy in type 1 
diabetes.
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4. MATERIALS AND METHODS
4.1. Study subjects and clinical samples
Samples of normal human kidney were obtained from cadaver donors 
inappropriate for transplantation due to vascular anatomic reasons (De-
partment of Surgery, Helsinki University Central Hospital), and glomeruli 
were extracted from the cortical kidney tissue using the graded sieving 
method [176] (Study I). Primary cultures of human podocytes (chapter 
4.3) were established from kidney specimens obtained from renal carci-
noma patients undergoing nephrectomy.
Two sets of patients were selected for quantitative RT-PCR analysis of 
fi ltrin (KIRREL2), nephrin (NPHS1), and podocin (NPHS2) mRNAs (Study 
III). The fi rst set of 69 kidney biopsies was collected within the European 
Renal cDNA Consortium (members listed in Appendix I), and the biopsies 
were divided into the following groups according to histological diagno-
sis (Table 2). In these samples, the glomerular compartment was microdis-
sected and processed for RNA isolation as described previously [177]. The 
second set of samples was collected at the St. Vincent’s Hospital (Fitzroy, 
Australia; Table 2), and total RNA was extracted from whole biopsies. 
Nonaffected parts of tumor nephrectomies served as a control group.
For immunohistochemical examination of fi ltrin in injured glomeruli, 
a total of 15 biopsies obtained for routine diagnostic purposes at the San 
Carlo Borromeo Hospital (Milan, Italy) were used (Study III). The diagnos-
tic groups of the biopsies were as follows: minimal change disease (n = 
4), membranous glomerulopathy (n = 6), and focal segmental glomeru-
losclerosis (n = 5). In addition, renal samples of the tumor-free part of 
nephrectomy specimen were used as controls (n = 3). 
Two groups of Finnish patients with type 1 diabetes with and without 
diabetic nephropathy were selected for the genetic association analysis of 
densin-180 (LRRC7), NEPH1 (KIRREL), podocin (NPHS2), fi ltrin (KIRREL2), 
and α-actinin-4 (ACTN4). The patients were part of the Finnish Diabetic 
Nephropathy (FinnDiane) Study (Study IV). First, the extensive screening 
of single nucleotide polymorphisms (SNPs) was performed in 1103 pa-
tients. Second, an additional set of 1025 patients was analysed in order 
to confi rm the positive fi ndings (Table 2). The renal status of the patients 
was based on the albumin excretion rate (AER). Normoalbuminuria was 
defi ned as AER below 30 mg/24h (< 20 μg/min in an overnight urine col-
lection), microalbuminuria as AER of 30-300 mg/24h (20-200 μg/min), and 
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Table 2. Clinical characteristics of analyzed subjects.
Diagnostic group n
Age 
(years)
Serum creatinine 
(µmol/l) Proteinuria (g/24h)
European Renal cDNA Consortium
Control subjects 7 64±6 NA NA
Minimal change disease 13 36±16 101±44 5.7 (0.2 - 14.8
Hypertensive nephropathy 16 56±10 172±151 1.0 (0 - 2.6)
Membranous glomerulopathy 31 55±23 130±108 4.9 (0.4 - 17.0)
Focal segmental glomerulosclerosis 9 47±16 128±45 2.3 (0.2 - 10.4)
St. Vincent’s Hospital
Control subjects 6 NA NA NA
Membranous glomerulonephropathy 4 65±4 125±50 4.1 (1.9 - 8.0)
Diabetic nephropathy 7 51±19 173±80 1.2 (0.6 - 21.2)
Minimal change disease 5 31±12 86±21 8.2 (6.3 - 14)
Focal segmental glomerulosclerosis 11 56±19 145±42 4.0 (1.0 - 14.0)
FinnDiane - 1st set of patients AER (mg/24h)
Normoalbuminuria 459 43±10 85±15 7 (1 - 85)
Microalbuminuria 276 37±11 90±19 59 (2 - 613)
Macroalbuminuria 368 39±9 165±125 588 (4 - 8348)
FinnDiane - 2nd set of patients
Normoalbuminuria 607 40±12 83±17 8 (1 - 101)
Macroalbuminuria 158 45±10 163±114 426 (11 - 4609)
End-stage renal disease 260 44±8 - -
Data are summarized as mean ± standard deviation or median (range). AER, albumin excretion 
rate; NA, not available.
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macroalbuminuria as AER over 300 mg/24h (> 200 μg/min) in two out of 
three consecutive urine collections [178]. Patients with normoalbuminu-
ria were required to have duration of diabetes over 15 years. Patients on 
dialysis or with a kidney transplant were considered to have an end-stage 
renal disease (ESRD).
Informed consent was obtained from all subjects. The study protocols 
followed the principles of the Declaration of Helsinki and were approved 
by local ethics committees.
4.2. Animals
Normal rat kidneys (Sprague-Dawley) were used to explore the expres-
sion and localization of fi ltrin (Studies I and III). Glomeruli were isolated 
from the kidney tissue using the sieving method as previously described 
for the rat tissue [176]. Tissues (brain, kidney, pancreas, mesenteric and 
peripheral lymph nodes, spleen, and thymus) of adult male mice (strain 
NMRI) were prepared for the expression analyses of the Nphs1 and 
Nphs1as mRNAs (Study II). In addition, femoral and tibial bone marrow 
were harvested for preparing of dendritic cells [179]. Macrophages were 
obtained from peritoneal cavity after stimulation with intraperitoneally 
injected fetal calf serum. Macrophages were collected from the perito-
neal cavity with RPMI 1640 medium (BioWhittaker Europe, Verviers, Bel-
gium). The local research ethics committees approved all experiments.
4.3. Cell culture
Various cell lines and primary cell cultures were employed to investigate 
the expression pattern of fi ltrin, nephrin and Nphs1as (Studies I, II and 
III; Table 3)
4.4. Molecular cloning and mRNA expression analysis
Complementary DNA clones
The cDNA clones UI-M-BH2.1-apt-g-03-0-U (mouse Nphs1as cDNA) and 
DKFZp564A1164 (human fi ltrin cDNA)  were purchased from Research 
Genetics (Invitrogen, Paisley, UK) and RZPD Resource Center (Berlin, Ger-
many) for further experiments.
RNA isolation
Total RNA was isolated from tissues and cultured cells using chloroform-
phenol extraction in the presence of Trizol reagent (Life Technologies, 
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Gibco BRL, Paisley, UK) or with an RNA isolation kit (Atlas Glass Total 
RNA Isolation kit [Clontech, Carlsbad, CA, USA] and RNeasy kit [Qiagen, 
Hilden, Germany]) according to the manufacturers’ instructions. To re-
move traces of genomic DNA, isolated RNA was incubated with RNase-
free DNaseI (Promega, Madison, WI, USA) for 30 minutes together with 
human placental RNase inhibitor (Promega).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Several applications of reverse transcriptase-polymerase chain reaction 
(RT-PCR) were employed in gene expression analysis at the mRNA level. 
The methods included qualitative, (semi)quantitative, and orientation-
specifi c RT-PCR analysis, and, for mRNA cloning, rapid amplifi cation of 
cDNA ends (RACE).
Complementary DNA (cDNA) was synthesized from RNA using the M-
MLV (Promega) or AMV (Roche Diagnostic GmbH, Mannheim, Germany) 
reverse transcriptase enzymes using either oligo-dT15 primers or random 
hexamers (Roche Diagnostic GmbH). In orientation-specifi c RT-PCR anal-
ysis of the Nphs1 and Nphs1 as mRNAs, gene-specifi c oligonucleotides 
were used for priming the cDNA synthesis (Study II). Reactions without 
the reverse transcriptase enzyme served as negative controls.
Thereafter, the cDNA was amplifi ed using gene-specifi c primer pairs 
(Studies I and II) with AmpliTaq Gold DNA polymerase (Applied Biosys-
tems, Foster City, CA). In semiquantitative RT-PCR of Nphs1 and Nphs1as 
Table 3. Summary of cell culture experiments.
Cell culture Culture media Reference Study
Human podocytes DMEM containing 10% fetal calf serum, 2.5 mM 
glutamine, 0.1 mM sodium pyruvate, 5 mM HEPES 
buff er, insulin, transferrin, and 5 mM sodium selenite.
[232] I
Mouse dendritic cells RPMI 1640 medium with 10% fetal calf serum 
supplemented with 10 ng/ml murine recombinant 
GM-CSF.
[179] II
Mouse embryonic stem cell 
line 129/Sv
DMEM with 20% fetal calf serum containing 1000 
units/ml of leukemia inhibitory factor.
[233] II
Mouse epithelial cortical 
collecting duct cell line M-1
1:1 mix of Ham F12 medium and DMEM containing  
5% fetal bovine serum and 5 μM dexamethasone.
[81] II
Mouse insulinoma 
cell line MIN6
DMEM with GlutaMax-1 supplemented with 
15% fetal calf serum, 1 mM sodium pyruvate, 
and 0.05 mM β-mercaptoethanol.
[234] II
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(Study II), serial dilutions (1:5 - 1:125) of cDNA samples were amplifi ed 
within the linear range of the PCR reaction, and the mRNA levels were 
normalized to the house-keeping gene cyclophilin A (Ppia, peptidylprolyl 
isomerase A). Cyclophilin A can be considered a suitable internal refer-
ence gene for comparing the expression of a target gene between dif-
ferent tissues, since the expression of cyclophilin A is not restricted to 
a specifi c tissue or cell type [180]. The RT-PCR products were analyzed 
electrophoretically and visualized using ethidium bromide. Appropriate 
controls without the cDNA template were included in each experiment. 
The amplifi ed PCR products were confi rmed with DNA sequencing using 
an ABI 373 sequencer (Applied Biosystems, Foster City, CA, USA) and ABI 
Prism Dye Terminator kit (Applied Biosystems).
For quantitative real-time RT-PCR analysis of RNA isolated from hu-
man kidney biopsies, the gene expression assays were ordered from 
Applied Biosystems. Pre-developed assay reagents were used for fi ltrin 
(Assay ID: Hs00375638_m1) and glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH; Hs99999905_m1). According to a paper reporting the 
validation of internal reference genes for microdissected biopsies [181], 
the cyclophilin A mRNA was expressed at low levels in isolated glomeruli 
and was thus not suitable as a reference gene. Instead, GAPDH can be 
regarded as a potential housekeeping gene in microdissected glomeruli 
[181, 182]. For nephrin and podocin, previously developed forward and 
reverse primers and probes were used [47]. The gene expression measure-
ment was based on the TaqMan technology which utilizes the 5’-nuclease 
activity of the AmpliTaq Gold DNA polymerase and fl uorescently labeled 
gene-specifi c probe containing a reporter dye at the 5’-end of the probe 
and a quencher at the 3’-end of the probe. Each sample was measured in 
duplicate, and the PCR amplifi cation was performed with the ABI Prism 
7700 Sequence Detection System (Applied Biosystems) equipped with in-
strumentation for fl uorescence detection. The normalized expression of 
the analysed gene was calculated with the 2ΔCt method [177], where ΔCt 
was defi ned as Ct(gene) - Ct(GAPDH), Ct denoting the threshold cycle for 
each measurement.
For cloning the antisense transcript of the mouse nephrin gene 
(Nphs1as), RACE [183] was performed with the GeneRacer kit (Invitrogen) 
according to the manufacturer’s instructions using the gene-specifi c 5’- and 
3’-RACE primers (Study II). The nested PCR products were subcloned into a 
pCR4-TOPO vector (Invitrogen) and sequenced as described above.
Northern Blotting
The molecular weight of the Nphs1as mRNA was determined using the 
Northern blotting analysis [184]. RNA isolated from ES-cells (strain 129/
Sv) was separated with gel-electrophoresis and blotted onto a nylon 
membrane. The fi lter was hybridized with a [α−32P]UTP-labeled ribo-
probe. This strand-specifi c probe was synthesized with a T7 polymerase 
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(Promega) from the pCR4-TOPO vector containing the 3’-RACE fragment 
of the Nphs1as cDNA.
RNA dot blot assay
In order to get insight into the fi ltrin mRNA expression pattern in human 
tissues, an RNA dot blot technique was chosen, and Human Multiple Tis-
sue Expression (MTE™) Array (Clontech Laboratories) containing poly(A) 
mRNAs from 76 tissues was selected for the expression profi ling. Briefl y, 
[α−32P]dCTP labeled cDNA probe was synthesized with Rediprime II ran-
dom prime labeling system (Amersham Pharmacia Biotech, Uppsala, Swe-
den) using the insert of nucleotides 496-2273 from the DKFZp564A1164 
clone as a template. The MTE blot was hybridized overnight with the 
purifi ed (NICK column; Amersham Pharmacia Biotech) probe in a hybridi-
zation oven, and analyzed after an overnight exposure to a phosphoim-
ager plate at -75°C with a Bio-imaging analyzer (Fuji Photo Film co, Kana-
kawa, Japan).
4.5. Immunochemical methods
Antibodies
Polyclonal anti-fi ltrin antibodies were generated in rabbits, since fi ltrin 
was a novel and previously uncharacterized protein. Two hydrophilic oli-
gopeptides were selected from the fi ltrin protein sequence: The extracel-
lular peptide GPS PHF LQQ PED LVV LLG EE(C) represented the amino 
acids 21-40 of fi ltrin and was highly conserved in the rat and mouse. An 
additional cysteine  (C) was added for coupling the peptide to a carrier 
protein. The second peptide consists of the amino acids 533-548, CWR 
HSK ASA SFS EQK N, in the intracellular domain of fi ltrin. The peptides 
were synthesized, purifi ed, and coupled to the carrier protein keyhole 
limpet hemocyanin by Alpha Diagnostics International Inc. (San Antonio, 
TX, USA). Two rabbits (NZW strain) were immunized with each peptide 
according to standard protocols. Prior to immunizations, appropriate 
control serum samples were collected. The antiserum against the extra-
cellular peptide was immuno-purifi ed with the corresponding peptide 
coupled to Epoxy-Activated Sepharose CL-6B Resin (Sigma-Aldrich, St. 
Louis, MO, USA) to yield peptide-specifi c fractions, and antiserum against 
the intracellular peptide with the protein-A-sepharose (Amersham Bio-
sciences), respectively, following the manufacturers’ instructions.
The polyclonal anti-nephrin antibody was raised in rabbits immunized 
with a recombinant intracellular part of rat nephrin [88]. The antiserum 
was purifi ed with a protein-A-column to isolate IgG fractions. The mono-
clonal anti-synaptopodin antibody from Progen (Goettingen, Germany) 
was used as a podocyte-specifi c marker.
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Immunoblotting
The molecular weight and expression of fi ltrin and nephrin were de-
termined by immunoblotting in the kidney and other tissues. Tissue sam-
ples were homogenized in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% NP-40, 0.1% SDS and 0.5% sodiumdeoxycholate, pH 8.0) in the pres-
ence of a protease inhibitor cocktail (Complete Mini, EDTA-free, Roche 
Diagnostics). The detergent extracts were suspended in the Laemmli 
sample buffer [185], boiled for 5 minutes, separated with SDS-PAGE, and 
electrotransferred to nitrocellulose membranes (Amersham Life Sciences, 
Buckinghamshire, UK). Proteins were detected either with the intrac-
ellular anti-fi ltrin or with the anti-nephrin antibody followed by HRP-
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA) using the ECL method (SuperSignal West Pico 
Chemiluminescent Substrate kit; Pierce, Rockford, IL, USA).
Immunofl uorescence microscopy
The distribution of fi ltrin was investigated in the cortical kidney tissue 
from cadavers and in kidney biopsies from patients with proteinuric dis-
eases using immunofl uorescence microscopy (Studies I and III). Five μm 
thick frozen sections were fi xed with either ice cold-acetone or 3.5% 
paraformaldehyde in PBS followed by permeabilization with 0.1% Tri-
ton X-100 in PBS, and detected with the indirect immunofl uorescence 
method. Briefl y, the intra- or extracellular anti-fi ltrin antibodies were in-
cubated on the sections followed by appropriate fl uorescently-labelled 
secondary antibodies (FITC goat anti-rabbit IgG (H+L) [Jackson Immu-
noResearch Laboratories] or Alexa Fluor 546 goat anti-rabbit IgG [Molec-
ular Probes, Invitrogen]). In dual labeling experiments, the sections were 
incubated with the anti-synaptopodin antibody and Alexa Fluor 488 
goat anti-mouse IgG (Molecular Probes) as a secondary antibody prior 
to staining with the anti-fi ltrin antibody. The sections were embedded 
in an anti-fading aqueous medium and examined under a fl uorescence 
microscope equipped with appropriate fi lters. As a secondary antibody 
control, the primary antibodies were omitted or replaced with irrelevant 
IgGs. Additionally, the intracellular anti-fi ltrin was immunodepleted by 
preincubation with the antigenic peptide to confi rm the specifi city in im-
munofl uorescence analysis.
Immunoelectron microscopy
Subcellular localization of fi ltrin in podocytes was explored with indirect 
immunoelectron microscopy (Study III). Rat kidneys were perfusion fi xed 
with 4% freshly prepared paraformaldehyde in PBS. Ultrathin sections 
were incubated with the extracellular anti-fi ltrin antibody, followed by 
incubation with 10 nm gold-conjugated goat anti-rabbit IgG (1:50; Am-
ersham Biosciences).
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4.6. Genotyping
In Study IV, the genetic association of LRRC7, KIRREL, NPHS2, KIRREL2, 
and ACTN4 with diabetic nephropathy was investigated using a compre-
hensive set of bi-allelic single nucleotide polymorphisms (SNPs). The SNPs 
were selected from public SNP databases (Table 4). The Tagger program 
[186] was employed to select tag SNPs for ACTN4 and NPHS2 with pair-
wise r2 > 0.8. In LRRC7, KIRREL, KIRREL2 evenly distributed SNPs covering 
the gene loci were chosen. DNA was extracted from peripheral blood col-
lected from the patients. Genotyping was performed using the Homog-
enous MassExtend MassArray System (Sequenom, San Diego, CA, USA) 
based on the MALDI-TOF determination of primer extension products 
[187] or with the ABI Prism 7900 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) utilizing allele-specifi c TaqMan probes 
[188]. To assure genotyping accuracy, internal controls were included in 
each analysis.
4.7. Databases, bioinformatics tools, and statistical 
methods
Publicly available databases and bioinformatics search engines were 
utilized in searching for novel nephrin homologues (including fi ltrin 
[KIRREL2] and Nphs1as) and in gaining information about their gene 
structure and genomic localization, expression profi les and protein ar-
chitecture (Table 4). Genomic databases were employed for the selection 
of SNPs, and appropriate tools were selected to estimate the power of 
statistical tests and haplotype and linkage disequilibrium (LD) values of 
the analyzed genes (Table 4).
Continuous variables (clinical variables and gene expression data) are 
summarized as mean value ± standard deviation or median value (range). 
Differences between multiple groups for normally distributed variables 
were evaluated with ANOVA or the Dunnett 2-sided test, non-normally 
distributed variables were either log10 transformed prior to analysis or 
assessed with the non-parametric Kruskal-Wallis test. Pearson correla-
tion coeffi cients were calculated and their signifi cances were tested to 
evaluate correlation between two variables. Hardy-Weinberg calcula-
tions were performed to test genotype equilibrium for each SNP, and the 
genotype data were compared with the χ2-test. Logistic regression model 
with the nephropathy status as the dependent variable and risk factors 
as covariates was used to estimate the independent association of SNPs. 
Statistical analysis was performed with SPSS 12.0.1 for Windows software 
(SPSS Inc., Chicago, IL, USA).
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Table 4. Summary of bioinformatic databases and computational tools.
Database / Tool Description URL Study
AUG_EVALUATOR Prediction of translation start codons http://www.itba.mi.cnr.it/webgene/ I
BLAST Basic local alignment search tool http://www.ncbi.nlm.nih.gov/BLAST/ I, II
ClustalW Multiple sequence alignment tool http://www.ebi.ac.uk/clustalw/ I
CpGPlot Detection of 
CpG-rich regions in genomic DNA
http://www.ebi.ac.uk/emboss/cpgplot I, II
dbSNP Database of single nucleotide 
polymorphisms
http://www.ncbi.nlm.nih.gov/SNP/ IV
GenBank Database of genetic sequences http://www.ncbi.nlm.nih.gov/Genbank/ I, II
Genetic Power 
Calculator 
Power analysis of genetic 
association tests
http://pngu.mgh.harvard.edu/~purcell/gpc/ IV
Genome Browser Database of genetic information http://genome.ucsc.edu/ IV
Genscan Prediction of gene structures in 
genomic DNA
http://genes.mit.edu/GENSCAN.html I
Haploview Tool for haplotype and linkage 
disequilibrium analysis
http://www.broad.mit.edu/mpg/haploview/ IV
HapMap Database of human genetic variation http://www.hapmap.org/ IV
HCtata Prediction of TATA-signals in 
eukaryotic genes
http://www.itba.mi.cnr.it/webgene/ II
InterPro Database of protein families, 
domains and functional sites
http://www.ebi.ac.uk/interpro/ I
NetOGlyc Prediction of mucin type GalNAc 
O-glycosylation sites in proteins
http://www.cbs.dtu.dk/services/NetOGlyc/ I
Primer3 Tool for designing primers for 
exprssion analysis
http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi
I, II
Proscan Prediction of promoter regions http://bimas.dcrt.nih.gov/molbio/proscan/ I
Prosite Database of protein families, 
domains and functional sites
http://www.expasy.ch/tools/scanprosite/ I
SignalP Prediction of signal peptide cleavage 
sites in proteins
http://www.cbs.dtu.dk/services/SignalP/ I
Tagger Tool for the selection and evaluation 
of tag SNPs from genotype data 
http://www.broad.mit.edu/mpg/tagger/ IV
TMHMM Prediction of transmembrane helices 
in proteins
http://www.cbs.dtu.dk/services/TMHMM-
2.0/
I
UniGene Database of gene transtcripts http://www.ncbi.nlm.nih.gov/entrez/ I, II
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5. RESULTS
5.1. Filtrin, a novel nephrin-like protein, is expressed in 
glomerular podocytes (Studies I and III)
The NCBI BLAST algorithm was used to search for uncharacterized cDNA 
clones and expressed sequence tags (ESTs) homologous to human ne-
phrin. The cDNA clone DKFZp564A1164, originally isolated from the 
human fetal brain, was chosen as the candidate molecule for detailed 
analysis. This molecule was named ‘fi ltrin’, and the offi cial gene name 
provided by the HUGO Gene Nomenclature Committee is ‘kin of irre like 
2’ (KIRREL2) due to its similarity with D. melanogaster irre.
The sequence analysis revealed that fi ltrin is a type I transmembrane 
protein of the immunoglobulin superfamily of adhesion proteins. It is 
composed of a cleavable N-terminal signal sequence, fi ve extracellular 
immunoglobulin-like domains followed by an acid alpha-helical trans-
membrane region, and a cytoplasmic carboxy-terminal domain with a 
proline-rich region (Study I; Figure 4). Several putative N- and O-glyco-
sylation sites were detected at the extracellular side, and the cytoplasmic 
domain has potential phosphorylation sites at serine, threonine or tyro-
sine residues. The full-length form of fi ltrin consists of 708 amino acids. 
In addition to sequence homology to human nephrin (30%), fi ltrin shows 
considerable homology and structural similarity to the nephrin-like pro-
teins NEPH1 (44%) and NEPH2 (41%) (Table 5).
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Figure 4. Schematic domain composition of the nephrin-like proteins. The proteins 
consist of fi ve extracellular immunoglobulin-like domains (Ig) followed by a transmem-
brane domain (TM) and a cytoplasmic domain with the Grb2-SH2 and PDZK1 binding 
sites. The nephrin-like proteins interact with their cytoplasmic Grb2-SH2 and PDZK1 
binding sites with podocin and ZO-1, respectively. SP, signal peptide. Drawn after [57].
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The human fi ltrin gene KIRREL2 resides on chromosome 19q13.12 ad-
jacent to NPHS1 encoding nephrin (Study I). It is of particular note that 
NPHS1 and KIRREL2 are transcribed in the opposite directions, and the 
distance between the transcription start sites is approximately 5 kb in hu-
mans and 3 kb in the mouse and rat. This chromosomal arrangement is 
conserved among the species (Figure 5). In addition to the full-length form 
of fi ltrin, alternatively spliced variants of the fi ltrin mRNA were discov-
ered. The alpha-form lacks exon 4, potentially deleting a part of the extra-
cellular immunoglobulin-like domains of the translated protein, and the 
beta-forms represents a variant consisting only of the sequence coding for 
the signal peptide fused to the carboxy-terminal intracellular part of the 
protein (Study I). As reported by Sun and colleagues [56], the spectrum of 
alternatively spliced variants was broadened with the cloning of a mRNA 
variant, which lacks exon 2.
Two independent methods were employed to detect the expression 
of fi ltrin in the kidney. First, the fi ltrin mRNA was successfully amplifi ed 
from the isolated human and rat glomeruli and from the cultured hu-
man podocytes with RT-PCR (Study I). Second, anti-fi ltrin antibodies were 
raised in rabbits to explore fi ltrin at the protein level, and the antibodies 
were affi nity-purifi ed to reach maximal specifi city. The immunoblotting 
studies of the glomerular lysates with the extracellular anti-fi ltrin anti-
body showed the presence of a protein band with an apparent molecular 
weight of 107 kDa (Study I). In addition, the cultured human podocytes 
expressed protein isoforms of varying molecular weight. The difference 
between the theoretical molecular weight of 75.1 kDa and the experi-
mentally verifi ed size of 107 kDa may be explained by post-translational 
modifi cation by N- or O-glycosylation or other covalent modifi cations.
Table 5. Nephrin and the nephrin-like proteins, the genes encoding them and molecular charac-
teristics.
  Chromosomal location Protein
Protein Gene Human Mouse Size (aa) Molecular weigth (kDa)
Nephrin NPHS1 19q13.12 7qB1 1241 180
NEPH1 KIRREL 1q23.1 3qF1 757 90-110
NEPH2 KIRREL3 11q24.2 9qA4 778 100-125
Filtrin/NEPH3 KIRREL2 19q13.12 7qB1 708 107
The size of the protein is given in the number amino acids, and the apparent molecular weight 
represents the full-length isoform. The chromosomal regions are from the UCSC Genome Browser 
(March 2006 Assembly for human; February 2006 for mouse). aa, amino acid; kDa, kilo Dalton.
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Figure 5. The genomic organization and exon-intron structure of the human NPHS1 
and KIRREL2 genes in 19q13.12. Their transcription initiation sites are separated by 
a stretch of 5 kb, possibly sharing common regulatory elements. The arrows indicate 
the 5’-3’ direction of the mRNA transcription (Study I).
In order to obtain an insight into the global expression pattern of 
fi ltrin in human tissues, both bioinformatics and experimental methods 
were utilized. First, the expression of the fi ltrin-specifi c mRNA was ex-
plored with the EST sequence analysis: The UniGene cluster Hs.145729 
contained EST sequences isolated from the lung, eye, lymphatic tissue, 
pancreas, brain, kidney, and pituitary gland (Study I). Second, the expres-
sion pattern was deciphered with hybridizing the radioactively labelled 
fi ltrin-specifi c probe to the nylon fi lter containing poly(A) mRNAs from 
72 human tissues. According to the RNA dot blot analysis, fi ltrin mRNA is 
primarily expressed in the lymph nodes and the pancreas (Study I).
The distribution of fi ltrin in the kidney was examined with immuno-
histological methods. Immunofl uorescence staining with the extracel-
lular anti-fi ltrin antibody revealed expression in the glomerulus and to 
some extent in proximal and distal tubules (Study I). According to the 
staining with the intracellular antibody, fi ltrin is expressed in an epi-
thelial cell-like pattern in the glomerulus (Figure 6A; Study III). Most of 
the fi ltrin expression within the glomerulus was confi ned to podocytes 
as indicated by immunofl uorescent double labeling with the podocyte 
marker synaptopodin (Study III). The expression of fi ltrin was also ex-
amined at the ultrastructural level in podocytes, and the results indicate 
that fi ltrin localizes at the slit diaphragm of the podocyte foot processes 
(Figure 7; Study III).
5.2. Nphs1as mRNA is transcribed from the nephrin locus 
in a reverse orientation in the brain and lymphoid 
tissue (Study II)
The characterization of the nephrin-defi cient mouse model generated 
by random insertional mutagenesis revealed that the gene-trap vector 
PT1βgeo, containing an Engrailed splice-acceptor site fused in-frame 
to the LacZ/neomycin fusion gene [189], was integrated in an inverted 
orientation in exon 8 of the Nphs1 gene [190] (Figure 8B). Notably, the 
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Figure 6. Distribution of fi ltrin in the kidney glomerulus as shown by immunofl uo-
rescence microscopy. (A) Filtrin is expressed in an epithelial cell-like pattern in the 
normal glomerulus. (B) In  primary FSGS, a decrease in the fi ltrin staining can be 
observed, ranging from segmental to global. 
Figure 7. (A and B) On immunoelectron microscopical examination, gold particles 
were detected at the slit diaphragm area suggesting that fi ltrin localizes at the slit 
diaphragm. US, urinary space; GBM, glomerular basement membrane (Study III).
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trapped ES-cells were successfully screened by the selection marker gene 
and 5’-RACE, indicating the presence of an actively transcribed gene in 
an antisense orientation to nephrin. To elucidate this issue, Nphs1-like ex-
pressed sequence tags (ESTs) were searched from dbEST using the BLAST 
tool at NCBI. Among several positive hits, the clone UI-M-BH2.1-apt-g-
03-0-UI, originally isolated and sequenced from the mouse brain (strain 
C57BL/6J), showed exact complementarity, however, in an antisense ori-
entation (Figure 8A; Study II). 
An orientation-specifi c RT-PCR technique was chosen to exclude pos-
sible sequence artifacts and to confi rm that the clone represents a true 
mRNA transcribed from the Nphs1 locus. Several primer pairs were de-
signed with the help of the cDNA clone UI-M-BH2.1-apt-g-03-0-UI and 
the Nphs1 cDNA. This analysis confi rmed the presence of the Nphs1as 
mRNA in the mouse brain (strain NMRI) and embryonic stem (ES) cells 
(strain 129/Sv). No PCR product could be amplifi ed from cDNAs prepared 
from the kidney and pancreas, suggesting that these tissues do not ex-
press Nphs1as. All tissues examined and the ES cells expressed the Nphs1 
mRNA (Study II). Notably, the amplifi cation of Nphs1as was only success-
ful with the primer pair crossing the intron 7 of Nphs1 (Figure 8A), which 
is in agreement with the alignment of the EST clone UI-M-BH2.1-apt-g-
03-0-UI with the genomic sequence. More extensive screening of mouse 
lymphoid tissues indicated that the Nphs1as mRNA is transcribed in the 
thymus, peripheral lymph nodes and dendritic cells, whereas no expres-
sion was observed in the mesenteric lymph nodes, spleen and macro-
phages (Study II).
Figure 8. Nphs1as is transcribed from the nephrin encoding locus in a reverse orienta-
tion. (A) Genomic location and exon–intron structure of Nphs1 and Nphs1as mRNAs. 
Locations of the primers 2s/2as and 2Bs/2Bas used to amplify Nphs1as in Study II are 
indicated. (B) Targeting vector PT1βgeo disrupts exon 8 of Nphs1 in the nephrin-
defi cient mouse model. Notably, the vector is integrated in an inverted orientation. 
CpG, CpG island  (Study II).
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Mounting evidence of the existence of the nephrin antisense tran-
script encouraged us to proceed to cloning the full-length cDNA. A tech-
nique known as the Rapid amplifi cation of cDNA ends (RACE) [183] was 
utilized to clone both the 5’- and 3’-ends of the transcript from the wild 
type murine brain RNA. The assembly of the isolated RACE-fragments 
with the sequence of the clone UI-M-BH2.1-apt-g-03-0-UI revealed that 
Nphs1as is a continuous 1339 bp mRNA (Study II). Northern blot analysis 
was used to further examine the molecular weight of Nphs1as mRNA. An 
RNA blot from embryonic stem cells was hybridized with a strand-specifi c 
3’-RACE riboprobe. The size of the single transcript of approximately 1.5 
kb detected in the analysis accords with the length of the Nphs1as cDNA 
isolated with RACE (Study II).
Based on the information of the Nphs1 exon-intron structure [191], 
the transcription of Nphs1as initiates from the Nphs1 exon 12 and ex-
tends until intron 6 (Figure 8A). Nphs1as is composed of three exons with 
consensus GT-AG splice sequences: the nucleotides 1-143 form exon 1, 
144-558 exon 2, and 558-1339 exon 3. It is likely that the isolated se-
quence contains a genuine 3’end since poly(A)-tail was located at the end 
and multiple poly(A) signal sites (nucleotide positions 1125-1137) were 
present near the A-rich region. These sites were not completely identical 
with the conserved AAUAAA or AUUAAA eukaryotic signal sequences 
[192], possibly reducing the accuracy or effi ciency of poly(A) tail forma-
tion. A translated protein is not to be expected, because the sequence 
analysis did not revealed an open reading frame.
To throw light on the possible correlation between the Nphs1 and 
Nphs1as levels and nephrin protein expression, semiquantitative RT-PCR 
of the sense and antisense transcripts and immunoblotting with nephrin-
specifi c antibody were employed. Immunoblotting analysis identifi ed a 
double band of 185 kDa and 165 kDa in the kidney lysates, and a protein 
of 165 kDa in the lysates from the pancreas and brain (Study II). The 
intensity of amplifi ed RT-PCR products in dilution series of the cDNAs 
(from 1:5 to 1:125) was evaluated visually after gel-electrophoresis. In 
tissues expressing the sense and antisense transcripts, the level of the 
Nphs1as mRNA was remarkably higher in the brain than in peripheral 
lymph nodes and thymus. The Nphs1 mRNA was present in similar levels 
in the brain and peripheral lymph nodes, whereas the thymus expressed 
only a fraction of the other two (Study II).
5.3. Glomerular expression of fi ltrin in patients with 
proteinuric kidney diseases (Study III)
The expression of fi ltrin was examined in patients with proteinuric kidney 
diseases. First, fi ltrin mRNA expression was analyzed in isolated glomeruli 
from patients with focal segmental glomerulosclerosis (FSGS), minimal 
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change disease (MCD), hypertensive nephropathy (HT), and membranous 
glomerulonephropathy (MGN). Control samples were obtained from the 
healthy kidney poles of individuals who underwent tumor nephrectomies. 
By real-time quantitative RT-PCR, the ratio of fi ltrin mRNA to GAPDH mRNA 
was determined. In addition, the levels of nephrin and podocin mRNA 
were measured from the same samples. Compared with control kidneys (n 
= 7), statistically signifi cant under-expression of fi ltrin was observed in all 
diagnostic groups, with the highest repression in patients with FSGS (n = 9, 
p = 4.5·10-6) and MGN (n = 31, p = 0.3·10-6; Figure 9A). 
Second, expression ratios of fi ltrin/nephrin and fi ltrin/podocin were 
calculated in order to adjust the levels of fi ltrin to the podocyte marker 
genes (Figure 9B). This confi rmed the reduced expression of fi ltrin mRNA 
in relation to the podocyte markers in proteinuric diseases, thus over-
coming the possibility that the observed decrease was due to a reduced 
number of podocytes per glomerulus. In addition, a positive correlation 
was observed in the glomerular fi ltrin/GAPDH and nephrin/GAPDH val-
ues (n = 63, r = 0.72, p = 2.9·10-11). 
Third, replication of the mRNA results was performed in a second set 
of samples, where the cDNAs were prepared from whole biopsies. The 
results were in agreement with the previous analysis in the case of FSGS 
(n = 11, p = 1.6·10-3) and also revealed a decrease in patients with diabetic 
nephropathy (n = 7, p = 5.1·10-3) compared to controls (n = 6). In MGN 
and MCD, the decrease in fi ltrin mRNA did not reach statistical signifi -
cance. In spite of the general decrease in fi ltrin mRNA levels in proteinu-
ric diseases, no correlation was observed with the expression of fi ltrin 
and the levels of proteinuria or serum creatinine at the time of biopsy. 
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Figure 9. (A) Expression of the fi ltrin mRNA in glomerular diseases in the ERCB 
samples. The results are normalized to the GAPDH gene. (B) An alternative normali-
zation method was applied, where fi ltrin mRNA levels were adjusted to the nephrin 
mRNA levels in each sample. CON, control group (non-affected parts of tumour 
nephrectomies); MCD, minimal change disease; HT, hypertensive nephropathy; MGN, 
membranous glomerulopathy; FSGS, focal segmental glomerulosclerosis  (Study III).
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Collectively, these results indicate that the mRNA expression of fi ltrin is 
decreased in kidneys of patients with proteinuric kidney diseases.
A moderate staining intensity of fi ltrin was observed in the glomeru-
lus of patients with MCD (n = 4) and MGN (n = 6) as compared to controls 
(n = 3) in immunohistochemical examination. In MCD, fi ltrin was also 
detected in the mesangium, whereas in MGN, the glomerular staining of 
fi ltrin appeared granular. A marked decrease in the glomerular staining 
of fi ltrin characterized patients with FSGS (n = 5), ranging from segmen-
tal to global (Figure 6).
Figure 10. The exon-intron structure of the ACTN4 gene, with the chromosomal 
location of the genotyped SNPs. The marker-marker linkage disequilibrium (LD) plots 
are presented with r2 values (white = 0, 0 < grey < 1, black =1).  Haplotype blocks of 
strong LD are indicated. LD, linkage disequilibrium  (Study IV).
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5.4. Genetic association analysis of LRRC7, KIRREL, NPHS2, 
KIRREL2, and ACTN4 with diabetic nephropathy 
(Study IV)
To investigate the genetic association of selected nephrin-associated 
genes with nephropathy in type 1 diabetes, a genetic association analysis 
was performed in a cross-sectional case-control study setting. A set of 
1103 Finnish type 1 diabetic patients was included into the fi rst analysis, 
and the patients were classifi ed as having normoalbuminuria (n = 459), 
microalbuminuria (n = 276), or macroalbuminuria (n = 368). In order to 
confi rm the results of the fi rst analysis, an analysis of patients with nor-
moalbuminuria (n = 607) and macroalbuminuria (n = 158) was performed 
for the selected SNPs at the second stage of analysis. In addition, a set of 
patients with ESRD (n = 260) was included.
In the fi rst screening, a total of 45 SNPs in the LRRC7, KIRREL, NPHS2, 
KIRREL2, and ACTN4 genes were genotyped for the association analysis 
(Study IV). Genotype distributions were in Hardy-Weinberg equilibrium 
(HWE) in all SNPs except in the LRRC7 SNP rs984950 (HWE p-value in pa-
tients with normoalbuminuria 2.2·10-6), indicating that the results of this 
SNP should be interpreted with caution. Statistical analysis revealed that 
no differences were evident in genotype, allele, or haplotype frequen-
cies between patients with normal albumin excretion rate and diabetic 
nephropathy. The independent association of the SNPs was evaluated 
by adjusting the genetic effect with duration of type 1 diabetes, systolic 
and diastolic blood pressure, and HbA1c. However, this did not change 
the results. Neither were the polymorphisms associated with the albumin 
excretion rate, serum creatinine level nor time from the onset of type 1 
diabetes to the development of diabetic nephropathy, when these vari-
ables were used as quantitative variables in the analysis instead of the 
categorical nephropathy status. Notably, this analysis included also pa-
tients with microalbuminuria. 
Since male gender has been considered as a risk factor for diabetic 
nephropathy in type 1 diabetes [124], males and females were also ana-
lyzed separately. The gender-specifi c analysis yielded modest genotype 
and allelic associations with diabetic nephropathy for the SNPs rs979972 
(p = 0.053), rs6508813 (p = 0.025), rs749701 (p = 0.008) and rs1060186 (p = 
0.025) in the ACTN4 gene in females. Figure 10 describes the exon-intron 
structure of the ACTN4 SNPs with the location of the genotyped SNPs. In-
terestingly, high pair-wise linkage disequilibrium (r2 > 0.8) was measured 
for the ACTN4 SNPs rs6508813-rs1060186. The four SNPs in the ACTN4 
gene reaching the statistical signifi cance level 0.05 were selected for the 
second stage of analysis.
At the second stage, a joint analysis of the genotypes from the fi rst 
and second set of patients was performed. The effect of stratifi cation 
by gender was investigated, since gender-specifi c effects were observed 
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already in the fi rst sample set. The SNPs rs979972 and rs749701 were as-
sociated with diabetic nephropathy and ESRD in females (Table 6). In this 
analysis, the genetic effect was adjusted for duration of type 1 diabetes, 
systolic and diastolic blood pressure, and HbA1c. For the SNPs rs979972 
and rs749701, p-values below 0.05 were detected in the Hardy-Weinberg 
equilibrium test in macroalbuminuric patients (Table 6). Interestingly, in 
the joint analysis of patients, the SNPs rs979972 and rs749701 yielded 
nominally signifi cant association with ESRD also in males, when the pa-
tients with normoalbuminuria and ESRD were compared (Table 6).
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Table 6. Four ACTN4 SNPs with evidence of an association with diabetic nephropathy. The patients of 
the fi rst and second stage of analysis were combined, minor allele frequencies are presented sepa-
rately for male and female patients with the corresponding adjusted odds ratios (OR) and p-values.
SNP  HWE MAFa Diabetic nephropathy ESRD
  p-value  ORb (95% CI) p-value ORb (95% CI) p-value
Males
rs979972 Normo 0.82 0.52 0.74 (0.48 - 1.15) 0.183 0.42 (0.21 - 0.85) 0.015
Macro 0.96 0.51
 ESRD 0.09 0.47     
rs6508813 Normo 0.55 0.27 0.64 (0.34 - 1.18) 0.153 0.60 (0.23 - 1.45) 0.244
Macro 0.70 0.24
 ESRD 0.33 0.27     
rs749701 Normo 0.44 0.44 0.65 (0.41 - 1.01) 0.057 0.43 (0.21 - 0.88) 0.021
Macro 0.69 0.40
 ESRD 0.11 0.40     
rs1060186 Normo 0.46 0.26 0.63 (0.34 - 1.19) 0.157 0.59 (0.24 - 1.47) 0.258
Macro 0.60 0.24
 ESRD 0.45 0.26     
Females
rs979972 Normo 0.56 0.51 1.81 (1.18 - 2.79) 0.007 2.26 (1.14 - 4.48) 0.020
Macro 0.03 0.56
 ESRD 0.08 0.60     
rs6508813 Normo 0.91 0.27 1.70 (0.98 - 2.94) 0.058 0.98 (0.37 - 2.59) 0.961
Macro 0.35 0.34
 ESRD 0.47 0.25     
rs749701 Normo 0.67 0.42 1.93 (1.25 - 2.96) 0.003 2.12 (1.05 - 4.28) 0.036
Macro 0.02 0.49
 ESRD 0.63 0.48     
rs1060186 Normo 0.54 0.26 1.73 (1.00 - 3.00) 0.052 0.86 (0.31 - 2.39) 0.766
Macro 0.33 0.34
 ESRD 0.72 0.25     
aMinor allele is defi ned as in Study IV. bThe ORs were adjusted for duration of type 1 diabetes, 
systolic and diastolic blood pressure, and HbA1c. Abbreviations: CI, confi dence interval; ESRD, end-
stage renal disease; HWE, Hardy-Weinberg equilibrium; Macro, macroalbuminuria; MAF, minor 
allele frequency; Normo, normoalbuminuria; OR, odds ratio.
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6. DISCUSSION
The hypothesis of this thesis stated that novel, yet unknown, nephrin-
associated molecules participate in maintaining the slit diaphragm func-
tion with nephrin. This has been proved to be at least partially true. 
Novel nephrin homologues NEPH1 [53], NEPH2 [54], and fi ltrin (Studies I 
and III) have been identifi ed and localized at the slit diaphragm. In addi-
tion, an endogenous nephrin antisense transcript Nphs1as was cloned in 
mouse (Study II), but to date no expression of Nphs1as has been detected 
in the kidney. 
Filtrin emerges into the picture of the podocytes
Filtrin is a novel nephrin-like protein of the immunoglobulin superfamily 
(Study I) [56, 57]. This is the fi rst study to determine the endogenous 
fi ltrin at the protein level in the kidney. The colocalization of fi ltrin with 
synaptopodin, an established podocyte marker, in dual immunofl uores-
cence microscopy of human kidney cortex together with the immunob-
lotting and RT-PCR data of isolated glomeruli support the expression of 
fi ltrin in the podocytes (Studies I and III). 
Nephrin is a crucial protein of the slit diaphragm [32-34]. Therefore, 
the question arises, which data support the association of fi ltrin with 
the slit diaphragm complex? At the ultrastructural level, immunoelectron 
microscopy using fi ltrin-specifi c antibodies indicates that fi ltrin localizes 
at the slit diaphragm area (Study III). In addition, fi ltrin, similar to the 
other nephrin-like molecules, interacts with the slit diaphragm proteins 
podocin and ZO-1 [57, 60]. Collectively, these data suggest that fi ltrin 
may belong, together with nephrin, to the cell adhesion junction be-
tween the podocyte foot processes. 
The nephrin-like proteins NEPH1, NEPH2 and fi ltrin all localize in the 
slit diaphragm, and experimental data suggest that NEPH1 and NEPH2 
form heterodimers with nephrin [35, 37, 54]. However, the dimensions of 
the extracellular domain of fi ve tandem immunoglobulin like repeats of 
the nephrin-like proteins might not allow direct interactions extending 
over the slit between the lateral foot process membranes. Instead, they 
may interact with the proximal part of the nephrin and, thus, stabilize 
the slit diaphragm structure as suggested by Tryggvason and colleagues 
[143]. Two other slit diaphragm proteins, nephrin and FAT1, are likely to 
be the ones that extend and form trans-interactions [34, 65]. Importantly, 
information on the signalling function for NEPH1 is emerging, involving 
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dynamic interactions with podocin and ZO-1, and NEPH1 seems to regu-
late podocyte gene expression [29].
Function of fi ltrin in other tissues
The expression profi ling of human tissues suggested that fi ltrin-specifi c 
mRNA is predominantly expressed in the pancreas and lymph nodes (Study 
I). The expression in the pancreas has been replicated in later studies, and 
immunohistochemical data suggest localization in the β-cells of the islets 
of Langerhans [56, 193]. Recently published data on patients with type 1 
diabetes indicates that anti-fi ltrin autoantibodies can be detected in the 
serum in approximately 10% of the patients during a follow-up time of 
10 years after the diagnosis of type 1 diabetes [194]. This suggests that 
fi ltrin is involved in the autoimmune destruction of pancreatic β-cell. In 
the case of nephrin and NEPH1, intravenous injection of the antibodies 
in experimental models results in proteinuria [25, 58], and it is tempting 
to speculate that fi ltrin in the podocytes could act as an autoantigen in 
patients with type 1 diabetes and ultimately predispose to diabetic neph-
ropathy. However, no evidence on the association of anti-fi ltrin autoan-
tibodies with diabetic nephropathy was observed in the clinical study by 
Rinta-Valkama and colleagues [194].  
In the brain, fi ltrin (NEPH3) appears transiently in the post-mitotic 
neural precursor cells, where it accumulates at the cellular processes and 
ZO-1 positive adherens junctions [195]. Confi rming the observation, fi ltrin 
localizes at the cell contacts in an adherens junction model in vitro. No-
tably, fi ltrin proteins were shown to form homophilic trans-interactions 
with each other [195]. In olfactory sensory neurons, fi ltrin and its homo-
logue NEPH2 act as homophilic adhesive molecules, and, interestingly, 
these proteins are expressed in a mutually exclusive pattern in the bun-
dle of axons  [196]. In these cells, fi ltrin presumably participates in axon 
guidance [196]. The podocytes have been described as neuron-like cells 
due to their characteristic morphology, and these cell types share some 
similarities at the molecular level [10].  However, it should be noted that 
the properties, especially the gap of 25 nm [197], of a typical adherens 
junction are not similar to the slit diaphragm. Thus the above mentioned 
results cannot be directly extrapolated to the mature slit diaphragm, 
where the lateral juxtaposed foot process membranes are separated by a 
distance of 30-40 nm [15].
Expression of nephrin and novel regulatory aspects
Expression of nephrin outside the kidney has been reported. In humans, 
nephrin has been associated with the islets of Langerhans in the pancreas 
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[193, 198] and the lymphoid tissue [199], but the fi ndings remain contra-
dictory (as reported in [200]) and may suffer from methodological limita-
tions. In the mouse, the expression pattern is also promiscuous including 
the pancreas and distinct parts of the brain [201]. In line with the expres-
sion profi le in humans, the nephrin mRNA was also successfully amplifi ed 
in the lymphoid tissue in mice (Study II).
Distinct promoter regions and alternatively used upstream exons may 
partly explain the tissue- and cell type-specifi c expression of nephrin 
[202-205]. Mechanistically, the transcription factors WT1, PPAR-gamma, 
and retinoic acid receptors participate in the regulation of nephrin at 
the promoter level [206, 207]. In addition, an alternatively spliced variant 
of NPHS1 mRNA has been isolated from the kidney [32]. The cloning of 
the endogenous antisense transcript of nephrin, Nphs1as, revealed yet 
another regulatory aspect of nephrin. Nphs1as is expressed in the brain, 
lymphoid tissue, and embryonic stem cells in the mouse (Study II), but, in 
contrast to the hypothesis, Nphs1as does not seem to be transcribed in 
the kidney and thus does not participate in the regulation of the slit dia-
phragm in the podocytes. It is reasonable to question, if Nphs1as mRNA 
is truly transcribed from the nephrin encoding locus in the mouse. How-
ever, sequence alignments of the isolated cDNA with the genomic DNA 
sequence (Study II) and the incorporation of the TRAP vector in exon 8 in 
the nephrin-defi cient mouse model [190] indicate that Nphs1as is tran-
scribed from the nephrin locus. The expression of nephrin mRNA in em-
bryonic stem cells has recently been confi rmed by independent research 
groups [208, 209]. 
The results presented here do not allow direct conclusions about the 
function of Nphs1as, but speculations can be presented based on previous 
knowledge of endogenous antisense transcripts: A number of functions, 
including transcriptional interference, RNA masking and double-stranded 
RNA-dependent mechanisms, has been attributed to endogenously ex-
pressed antisense transcripts (reviewed in [210]). As discussed by Lapidot 
and colleagues [210], the relationship between the expression pattern 
of Nphs1as and its target Nphs1 might give certain indications regard-
ing the mode of action. Nephrin is expressed in the brain in a cell-type 
specifi c manner [191, 201], and both the Nphs1as and Nphs1 mRNA are 
expressed in reasonable amounts (Study II). Thus, it can be proposed that 
the function of Nphs1as in the brain is to stabilize the Nphs1 mRNA tran-
script levels, but, of course, other mechanisms cannot be excluded. To my 
knowledge, the human counterpart of the nephrin antisense transcript 
has not been isolated. 
6 Discussion 49
Chromosomal organisation of KIRREL2 and NPHS1 in the 
human genome
The human fi ltrin gene KIRREL2 resides on chromosome 19q13.12 ad-
jacent to NPHS1 which encodes nephrin, and the distance between the 
transcription initiation sites is approximately 5 kb in human (Study I; Ta-
ble 5) and 3 kb in mouse and rat (data not shown). The inserted repeti-
tive DNA elements in the human DNA sequence may explain the differ-
ence in the distance of the intervening region. It has been demonstrated 
that the regulatory elements required for the endogenous Nphs1 expres-
sion pattern in the mouse are located 5.4 kb or even 8.3 kb upstream 
of the transcription initiation site [202]. Moreover, the region 1.25 kb 
upstream is shown to direct podocyte-specifi c expression both in human 
and mouse [203, 204]. Overlapping expression sites of nephrin and fi ltrin 
exist, particularly in the podocytes and the pancreatic beta-cells. Thus, 
the regulatory regions of NPHS1 and KIRREL2, although read in opposite 
directions, may overlap, suggesting the possibility of transcriptional co-
regulation. 
The head-to-head orientation of genes is a rather common phenome-
non, but the mechanisms of regulation of bi-directional genes are poorly 
known [211]. Systematic analysis of gene expression databases has re-
vealed that many bi-directional genes are coregulated but some, instead, 
are antiregulated [211]. In addition, transient transfection assays for a 
randomly chosen set of genes suggested that most bi-directional pro-
moters share gene regulatory elements that control both genes [211]. 
The TATA-element of the proximal promoter region is suggested to con-
tribute to the directionality of transcription and, therefore, bi-directional 
promoters contain very rarely TATA-boxes [211]. Interestingly, neither the 
NPHS1 nor KIRREL2 promoter has a TATA-box in their proximal promoter 
area (Study I).
Gene pairs coding for homologous proteins are uncommon. An exam-
ple of such a case is provided by the genes SAFB1 and SAFB2, which is a 
homolous gene pair arranged in a bi-directional divergent confi guration 
in 19p13.3 [212]. The genes are separated by a rather short intervening 
region of 500 bp and share similar functions as oestrogen receptors. They 
are widely co-expressed in human tissues, but the translated proteins 
have somewhat differing subcellular localizations [212].
On human chromosome 19, a conserved gene arrangement of orthol-
ogous genes in mouse and human has been described [213, 214]. Nota-
bly, one third of genes on chromosome 19 has been observed to belong 
to clustered gene families, possibly due to duplication of ancestral genes 
[214]. It appears that the nephrin and the nephrin-like genes are not 
confi ned to a single mammalian species, suggesting that chromosomal 
arrangements or duplications have occurred prior to the divergence of 
mammalian ancestors.
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Patients with proteinuria (Studies III and IV)
This study utilized several patient groups in elucidating the pathogenetic 
mechanism in proteinuria. Two sample sets were collected using a multi-
central approach. First, the Finnish FinnDiane cohort focusing on com-
plications in type 1 diabetes, particularly diabetic nephropathy, was uti-
lized for the genetic association analysis of the nephrin-associated genes 
(Study IV). Second, the European Renal cDNA bank, a multinational ini-
tiative to investigate the functional genetics of proteinuric renal diseases 
(participating centres listed in Appendix) was used for gene expression 
analysis of fi ltrin and the podocyte marker genes (Study III). The other 
two sample collections were derived from a single hospital in Fitzroy, 
Australia and in Milan, Italy, and were examined in Study III.
All clinical data were analysed in a cross-sectional setting (studies III 
and IV), which is a powerful study setting, when the phenotypes are well-
defi ned and the number of samples provides suffi cient statistical power. 
Ideally, the study setting would be a prospective one having follow-up 
data available after the time of collecting the samples. It is also note-
worthy that kidney biopsies usually represent a rather established stage 
of the disease, and may thus provide limited information on the early 
phases of the disease. Therefore, experimental animal models will be 
crucial to gain insight into the time perspective of the variation in the 
expression of fi ltrin and in order to exclude the effect of different envi-
ronmental effects.
Is fi ltrin merely a by-stander in the podocyte or is it 
involved in podocyte injury?
Mutations in the genes encoding nephrin (NPHS1) and NEPH1 (KIRREL) 
seem to trigger congenital nephrosis, and these molecules are indispensa-
ble for the maintenance of the slit diaphragm. We tested the hypothesis, 
whether fi ltrin is involved in the primary glomerular diseases including 
minimal change disease, focal segmental glomerulosclerosis and mem-
branous glomerulopathy (Study III). The mRNA levels of fi ltrin, nephrin, 
podocin and GAPDH were measured in kidney biopsies. GAPDH was used 
for standard normalization and nephrin and podocin were considered 
established podocyte marker genes. Two set of patients (ERCB and the 
St. Vincent Hospital) were analyzed. Collectively, the results indicate that 
fi ltrin is down-regulated in patients with primary glomerular disease in 
relation to GAPDH and also to the podocyte marker gene nephrin and 
podocin. The sample size was limited but still suffi cient to detect a statis-
tically signifi cant difference in expression values in all diagnostic groups 
in the ERCB samples, whereas in the second set of samples from the St. 
Vincent’s Hospital the low number of patients per diagnostic group and 
6 Discussion 51
high variability in the expression values did not allow drawing defi nitive 
conclusions in all disease categories (Study III). A statistically signifi cant, 
positive correlation (p ≈ 2.9·10-11) was observed in the expression values 
of fi ltrin and nephrin. This result gives additional support for the view 
that the gene expression in the podocyte is orchestrated potentially via 
common regulatory pathways. In addition, it is particularly interesting 
due to the intriguing chromosomal arrangement of the nephrin and fi l-
trin genes NPHS1 and KIRREL2. 
Altered distribution of fi ltrin in the glomerulus was observed in pa-
tients with glomerular diseases, especially in FSGS (Study III), which sup-
ports the results of the gene expression analysis. Can the nephrin-like 
proteins mutually compensate each other’s function? It is known that the 
nephrin-like proteins are only homologous in their extracellular domains 
but not in the intracellular domain (except the podocin-interacting do-
main) [57], and these structural differences may indicate that these pro-
teins do not have identical signal transductions mechanisms. 
The measurement of mRNA levels in kidney samples does not perfectly 
represent the gene expression activity. It rather refl ects the steady-state 
level of mRNA turnover, where degradation, modifi cations and transcrip-
tion have all their own effects. As for the podocytes, altered podocyte 
number due to their detachment from the basement membrane or pos-
sibly via apoptotic mechanisms may reduce the proportion of podocytes 
per glomerulus as reported in FSGS and diabetic nephropathy [129, 215]. 
Another concern is the number of glomeruli per one kidney biopsy. These 
facts may cause a bias in the expression analysis.
In this study, the concept of ‘in silico’ normalization according to the 
podocyte marker genes nephrin and podocin, originally introduced by 
the group of Dr. Matthias Kretzler [47], was successfully adapted for the 
expression analysis of fi ltrin (Study III). The results indicated that fi ltrin 
mRNA is down-regulated beyond the regulation of nephrin and podocin 
mRNAs, consistent with an mRNA repression per podocyte and not only 
a consequence of podocyte loss. This allowed us to overcome - at least 
partially - the concerns mentioned above. Furthermore, the effect of dis-
secting the kidney biopsies into distinct glomerular and tubulointerstitial 
compartments (described in [177]) was also evaluated in this study. The 
expression of fi ltrin in microdissected glomeruli was compared to that 
measured from whole biopsies (Study III). It appeared that a trend of 
decreased expression was observed in both sample sets, irrespective of 
the mode of the preparation of the samples (Study III). Based on the 
knowledge of the pathogenesis of ‘podocyte diseases’, additional means 
of normalization should be taken into use (including the ‘in silico’ nor-
malization) beyond the normalization in the house-keeping genes like 
GAPDH, which has been a golden standard in renal research.
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Can the genes behind monogenic proteinuric 
diseases contribute to the understanding of diabetic 
nephropathy?
Most of the current understanding of common diseases derives from 
the elucidation of the molecular background of rare familial forms of 
these common traits (discussed in [216]). The genes underlying the he-
reditary proteinuric diseases are expressed in the podocytes and include 
several slit diaphragm associated genes (chapter 2.5). In this study, we 
tested the hypothesis, whether the genes encoding fi ltrin, NEPH1, po-
docin, α-actinin-4 and densin-180 act as susceptibility genes for diabetic 
nephropathy (Study IV). The kidney complication of diabetes manifests 
fi rst with microalbuminuria [127], which suggests that the glomerular 
capillary wall, responsible for retaining albumin within circulation, is af-
fected.
The selection of the population is critical for the validity of the re-
sults of association analysis in complex diseases. The homogeneity and 
structure of the Finnish population is defi nitely an asset for performing 
genetic studies (reviewed in [217]). The Finnish population has a charac-
teristic disease heritage, and many of these diseases have a Mendelian 
pattern of inheritance. Several causative genes have been successfully 
identifi ed, including NPHS1 [27]. The population has also proved useful 
for complex disease genetic mapping, as illustrated by the mapping of 
susceptibility gene for asthma [218]. A recent population based study 
supports the involvement of a genetic component in diabetic nephropa-
thy in the Finnish population [163]. In addition, Finland has the highest 
incidence rate of type 1 diabetes in the world [219].
For the genes ACTN4 and NPHS2, tag SNPs were selected based on the 
HapMap data in the CEPH (Centre d’Etude Polymorphism Humain) popu-
lation. This approach assumes that the information content of the tag 
SNPs in the CEPH population is transferable to the Finnish population. 
The issue of tag transferability was recently examined by de Bakker and 
colleagues [220]. They estimated the correlation (r2) in the genotype data 
of a set of candidate genes between the CEPH population and the Botnia 
sample from Finland, and the results indicate that it is justifi ed to utilize 
the HapMap data for selection of tag SNPs for genotyping in the Finnish 
population without compromising the statistical power. A spacing ap-
proach (with an interval of 6-14 kb) was employed in the selection of the 
genotyped SNPs for KIRREL and KIRREL2. The HapMap data were utilized 
also in this selection, but not all tag SNPs were included in genotyping 
due to the large number of SNPs that the complete covering of these 
relative small genes would have required. In the case of LRRC7, only a 
few SNPs were genotyped, so it can only be considered as a pilot study.
The results of the genetic association analysis suggest that poly-
morphisms in the ACTN4 gene, encoding α-actinin-4, may be involved 
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in susceptibility to diabetic nephropathy in type 1 diabetes (Study IV). 
However, the link between ACTN4 and diabetic nephropathy was not 
straightforward, but a genetic interaction of the gender and the ACTN4 
polymorphisms was observed. The results were supported by the fi nding 
that the same variants also seemed to associate with cardiovascular dis-
ease (Study IV). Furthermore, the genotype distribution of the polymor-
phisms showed a deviation from the Hardy-Weinberg equilibrium in the 
female patients with macroalbuminuria (Study IV), which may indicate a 
true genetic association as proposed by Nielsen and colleagues [221].
α-actinin-4 is an actin-fi lament cross-linking protein located in the 
proximity of the slit diaphragm in podocyte foot processes [82, 83]. The 
structure and function of the cytoskeleton are of pivotal importance for 
maintaining the cell shape of the podocytes, and disturbances of the po-
docyte cytoskeleton have been detected in the presence of high glucose 
both in vitro and in vivo [222]. Interestingly, α-actinin-4 is down-regu-
lated in kidney biopsies of diabetic patients with microalbuminuria as 
compared to controls [223], and its expression is also disturbed in cul-
tured cells by diabetes-related pathogenetic factors including advanced 
glycation end-products [224].
The connection between ACTN4 and nephropathy was fi rst discov-
ered in patients with familial focal segmental glomerulosclerosis (FSGS) 
carrying mutations in the ACTN4 gene [83]. This disease belongs to the 
‘late-onset’ group according to the classifi cation by Kriz [142]. Regarding 
diabetic nephropathy, the complication develops gradually and the inci-
dence is at its highest after about 15 years’ duration of type 1 diabetes 
[124]. The results support the hypothesis that a gene previously linked 
to a rare monogenic type of nephropathy is also a good candidate for 
diabetic nephropathy, a more common type of nephropathy.
The statistical power was estimated for the genetic association analy-
sis [225]. While the fi rst set of patients alone remained underpowered to 
detect association with markers with low minor allele frequencies, the 
additional genotyping and the joint analysis of the patients at the sec-
ond stage of analysis increased the statistical power remarkably (Study 
IV). Low minor allele frequency (MAF) for certain genotyped SNPs may 
limit the interpretation of the results. Especially in KIRREL2, all SNPs had 
MAF under 0.05 in patients with a normal albumin excretion rate (Study 
IV). Therefore, direct sequencing of the KIRREL2 locus on chromosome 
19q13.12 to detect population-specifi c polymorphisms may be required. 
Furthermore, we cannot exclude the existence of rare variants in some 
cases of diabetic nephropathy.
It can be speculated that the mutation phenotype of the genes of mo-
nogenic proteinuria with a congenital onset of the disease, e.g. NPHS1 
and NPHS2, would not perfectly fi t with the insidious and slow patho-
genesis of diabetic nephropathy. On the other hand, the negative re-
sults of the association analysis might also arise from to the fact that the 
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genotyped SNPs covered only the coding region and the close vicinity of 
the genes under analysis. This approach assumed that causative muta-
tions locate in the coding, splicing site and/or regulatory regions in the 
proximity of the analysed gene. The causative variants may also reside 
over long distances from the coding region as exemplifi ed by the case 
of adult-type hypolactasia [226], and this possibility has to be taken into 
account when interpreting these results.
Even if the genotyped SNPs in the fi ltrin gene KIRREL2 were not associ-
ated with diabetic nephropathy, it appears that fi ltrin is down-regulated 
at the mRNA level in kidney biopsies of patients with diabetic nephropa-
thy (Study III). This seems to be the case with the nephrin gene NPHS1: 
NPHS1 has been excluded as a susceptibility gene for diabetic nephropa-
thy [227], but nephrin still seems to contribute to the pathogenesis of 
diabetic nephropathy. Decreased levels of nephrin are often observed in 
the glomerulus, and this seems to be mediated in an angiotensin II de-
pendent fashion [49, 51]. In addition, a similar down-regulation of fi ltrin 
mRNA was detected in another secondary glomerular disease hyper-
tensive nephropathy (Study III). Interestingly, diabetic and hypertensive 
nephropathy may have common predisposing factors and pathogenetic 
mechanisms [98].
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Concluding remarks
Since the cloning of the nephrin gene NPHS1, novel nephrin-associated 
molecules of pivotal importance for the slit diaphragm have been discov-
ered. This thesis adds two potentially interesting molecules to this list, 
and addresses their involvement in human glomerular diseases. It is of 
note that the term ‘nephrin-associated’ was interpreted in a quite broad 
sense in this thesis, including both nephrin-like and nephrin-interacting 
molecules. This thesis employed a bioinformatics approach for fi shing 
novel homologous genes and proceeded to assess the signifi cance of the 
molecules in pathological conditions by analysing human sample collec-
tions. This approach proved successful. Two novel candidates molecules, 
fi ltrin and Nphs1as, were discovered, and moreover, they are both tran-
scribed from the nephrin locus or its proximity.
Filtrin is a novel podocyte-expressed protein with localization at the 
slit diaphragm, and the expression of fi ltrin is down-regulated in human 
proteinuric diseases. However, several aspects of fi ltrin still deserve to be 
explored. Molecules of the immunoglobulin superfamily tend to form 
both homo- and heterodimers, and, therefore, it will be interesting to 
defi ne the molecular interactions of fi ltrin at the slit diaphragm - es-
pecially with nephrin and the nephrin-like proteins NEPH1 and NEPH2. 
Regarding the fi ltrin gene KIRREL2, an intriguing question is also the 
potential transcriptional co-regulation of KIRREL2 and NPHS1 in physi-
ological and pathological conditions. Whether or not these genes share 
common regulatory elements in their intergenic region remains to be the 
elucidated.
This thesis reports the discovery of Nphs1as, an endogenous antisense 
transcript of the nephrin gene, but this line of research was not continued 
due to the apparent lack of expression in the mouse kidney. Nevertheless, 
this does not rule out the possibility that Nphs1as could be biologically 
important. The possible human orthologue has not been cloned, and it is 
also tempting to speculate that de novo expression of the antisense tran-
script would emerge in the kidney under proteinuric conditions, which 
would provide an unprecedented view in the role of nephrin in glomeru-
lar diseases. It will be important to determine at which level (transcrip-
tion, pre-mRNA splicing, or translation) the possible interaction between 
Nphs1 and Nphs1as mRNAs occurs. These experiments may indicate novel 
regulatory functions of Nphs1as.
A candidate gene approach was selected to evaluate the genetic fac-
tors in diabetic nephropathy. It seems that common variants in ACTN4 
contribute to genetic susceptibility for diabetic nephropathy in type 1 di-
abetes. The results suggest that a gene previously linked to a monogenic 
focal segmental glomerulosclerosis (FSGS) may confer susceptibility to a 
secondary form of nephropathy, namely diabetic nephropathy. Replica-
tion of the fi nding in other populations and fi ne mapping of the gene 
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locus will be required. It is also worth examining the role of two other 
nephrin-associated genes TRPC6 and CD2AP in diabetic nephropathy. No-
tably, these genes have previously been linked to FSGS.
In conclusion, it seems that novel nephrin-like and nephrin-associated 
molecules are crucial for maintaining the function of the glomerular 
fi ltration barrier. The fi ndings presented in this thesis provide novel in-
sights into the molecular basis of human glomerular diseases and extend 
the understanding of the molecular anatomy of the slit diaphragm.
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